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ABSTRACT OF DISSERTATION

THE ROLE OF OXIDATIVE STRESS AND T CELLS IN THE DEVELOPMENT OF
MURINE SYNGENEIC GRAFT-VERSUS-HOST-DISEASE

Syngeneic graft-versus-host disease (SGVHD) is induced by reconstituting
lethally irradiated mice with syngeneic BM cells followed by a 21 day treatment with the
immunosuppressive agent cyclosporine A (CsA). Clinical symptoms of the disease
appear 2-3 weeks following cessation of CsA therapy and disease-associated
inflammation occurs primarily in the colon and liver.
The development of SGVHD is a complex process resulting from the cooperative
interaction of multiple effector cell populations including NK cells, T cells and
macrophages. TH1 cytokines (IL-12, TNF-α, IFN- γ), produced by these effector cells,
serve as inflammatory mediators contributing to the pathogenesis of SGVHD. The
SGVHD conditioning agents, irradiation and CsA, are both required for the development
of disease and contribute to the production of oxidative stress. Time course studies
revealed increased reactive oxygen and nitrogen species (ROS/RNS), as well as,
increased colon mRNA levels for TNF-α and iNOS in CsA-treated versus control BMT
animals. Since ROS/RNS are known to mediate CsA toxicity, studies were undertaken to
determine the effect of oxidative stress on the induction of SGVHD. In vivo treatment
with the antioxidant MnTBAP caused a reduction in colon mRNA levels for iNOS and
TNF-α, as well as delayed disease development, suggesting a role for oxidative stress in
the development of SGVHD.

In addition, CD4+ T cells have been shown to play an important role in the
inflammatory response observed in the gut of SGVHD mice. Time course studies
revealed significant increases in the migration of CD4+ T cells as early as day 14 postBMT into the colon of CsA mice as well as significant elevated mRNA levels of cell
adhesion molecules. Homing studies revealed that a labeled CD4+ T cell line, generated
from SGVHD mice, migrated in larger numbers into the gut of CsA-treated mice
compared to control animals. This study demonstrated that CD4+ T cells responsible for
the pathogenesis observed in murine SGVHD are present early after BMT in colons of
CsA-treated mice, suggesting that during the 21 days of immunosuppression therapy
functional mechanisms are in place that result in increased homing of effector cells to
colons of CsA-treated mice.

Key Words: Reactive Oxygen/Nitrogen Species (ROS/RNS), Manganese (III) mesotetrakis (4-benzoic acid) porphyrin (MnTBAP), Cell Adhesion Molecules (CAM), β7
integrin, T cell homing
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CHAPTER ONE: INTRODUCTION
1.1

Bone Marrow Transplantation
Bone marrow transplantation (BMT) is a medical procedure that was first applied

in 1968 to treat severe combined immunodeficiency diseases (SCID). In these studies
bone marrow (BM), taken from a major histocompatibility complex (MHC)-matched
donor, was able to correct the immunological deficiency of a patient with WiscottAldrich Syndrome (WAS) [1]. Since its first successful use, BMT/hematopoietic stem
cell transplantation (HCT) has been used as a treatment of choice for many diseases (i.e.
leukemia, aplastic anemia, immune deficiency disorders, etc.). The major complications
of BMT, graft rejection and graft-versus-host disease (GVHD) are the direct consequence
of human leukocyte antigen (HLA) (in mouse major histocompatibility complex, (MHC))
polymorphisms. The major HLA are essential components of the immune system and
have different functions. HLA class I antigens (A, B and C) present to T cells peptides
that are derived from endogenous cell components (or of viral origin), which are
produced from digested proteins that are broken down in the proteosomes. CD8+ killer T
cells are activated by the foreign antigens presented by HLA class I antigens and are the
effector cells responsible for the destruction of intracellular pathogens. HLA class II
antigens (DP, DQ and DR) present exogenous antigens derived from outside of the cell to
CD4+ T helper cells [2]. Helper T cells can be classified as to the types of cytokines they
produce and the nature of the adaptive immune response they generate. CD4+ T helper 1
(TH1) cells enhance cellular immune responses against intracellular pathogens via the
production of interferon γ (IFN-γ), that enhances macrophage activation and killing [2,
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3]. TH2 cells are involved in enhancing humoral immune responses via the production of
interleukin 4 (IL-4) and IL-5 [2, 3]. Finally, a recently described population of T helper
cells, TH17 cells, secrete IL-17 and participate in the response against extracellular
pathogens [4, 5].
The immune system uses the histocompatibility antigens to differentiate self from
non-self. Upon infection, antigen presenting cells (APC) recognize the pathogen by their
surface receptors (i.e toll like receptors (TLR)/pattern recognition receptors) and allow
binding by common constituents in the cell surface of the pathogen (i.e lipids,
carbohydrates, peptides or nucleic acids). This interaction allows the APC to engulf the
foreign pathogen through a process called phagocytosis. The ingested pathogen is
contained within a vesicle called phagosome that fuses with lysosomes, which are
acidified organelles containing degradative enzymes, to form a phagolysosome.
Lysosomal enzymes degrade the pathogen into small pieces. After encountering the
pathogen and taking it up in infected tissue, the APC becomes activated/mature and
carries pathogen antigens to peripheral lymphoid organs where they present them to T
lymphocytes [2]. This process allows for the digestion of proteins into small peptides,
which are then presented by self MHC class II to T helper cells or MHC class I to CD8+
T cells. This allows for immune responses to take place and elimination of the pathogen.
As the response is generated in the context of self-MHC, known as MHC restriction, selfreactivity is avoided. As T cells mature in the thymus, they first recognize peptides
bound to self MHC expressed by thymic APC. Immature T cells, capable of binding to
self-peptide-self MHC complexes at a proper affinity, undergo positive selection. If these
immature T cells have high affinity and/or cross reactivity for these self-peptides/MHC
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complexes they are eliminated by negative selection to avoid autoimmunity. Mature T
cells exit the thymus and migrate to the periphery where they encounter APC with
foreign-peptide-self MHC antigens and initiate an immune response. If on the other hand,
they encounter APC expressing self-peptides they do not react, a concept known as self
tolerance which prevents autoimmunity. However, if these T cells react to MHC
molecules, that they did not encounter during thymic development, it can lead to
alloreactivity. More than 1% of T cells can be activated by foreign (allogeneic) MHC
molecules [2]. This is a very high percentage relative to that observed in an immune
response to nominal antigen where the frequency of reactive T cells is on the order of
1:50,000–300,000 T cells in unprimed individuals and ~1:1000–10,000 T cells in primed
individuals [6, 7].
The two major complications of allogeneic BMT are graft rejection and GVHD
which develop when T cells from one individual recognizes the other’s individuals MHC
as foreign and respond against it [2, 8]. MHC polymorphisms are not the only donor-host
disparities that are involved in graft rejection. Differences in minor histocompatibility
antigens (miHA) can also cause the graft to be rejected slowly as well as to induce
GVHD [2, 9, 10]. Minor histocompatibility antigens are peptides derived from allogeneic
proteins that exist in various isoforms and can affect the fate of a graft by provoking cellmediated immune responses [9, 11]. In mice and other species there are at least 30 such
antigens [12]. While CD4+ and CD8+ participate in the immune response directed against
MHC antigens, CD8+ T cells are mainly responsible for immunity directed against miHA
[13, 14].
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Bone marrow transplants are classified based on the source of the donor marrow:
syngeneic if the BM is from an identical twin, autologous if it is isolated from the patient
or allogeneic if it is isolated from a HLA-matched sibling or unrelated donor. Allogeneic
BM recipients usually receive pretransplant conditioning regimens which include high
doses of chemotherapy and/or irradiation [15-18]. This therapy allows for the maximal
destruction of the abnormal cells causing the disease, typically malignant cells, as well as,
to eliminate the recipient’s hematopoietic/immune system that is required to avoid
immune responses against the donor cells and to allow proper engraftment, i.e. prevent
graft rejection [19, 20]. Alloantigens associated with the MHC molecules (Human: HLAA, B, C, DR, DQ; Mouse: H-2, I-E, I-A and miHA) are the major target of alloreactive T
cells that mediate patient immune reactivity against the donor BM underlying graft
rejection and GVHD after BMT [20, 21]. Most transplants preferentially take place
between donor and recipients that are HLA-matched siblings over HLA-matched
unrelated donors to reduce the possibility of graft rejection. During graft rejection, the
host's immune system initiates an effective response in which T lymphocytes recognize
the allo-MHC antigens as foreign and attack the transplanted tissue and destroy it [2].
Because of this destructive immune response, tissues from the patient and from potential
donors must be typed and matched as completely as possible before transplants are
performed to reduce the probability of graft rejection. Santos et al. described three
prerequisites for an effective conditioning to take place. First, the regimen must suppress
the recipient’s immunity to avoid graft rejection. Second, it must create a “space” in the
marrow microenvironment to allow establishment and growth of hematopoietic
progenitors. And third, for patients with malignant diseases, the conditioning must have
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an antitumor effect to eradicate residual tumor cells [22]. Thus, unless the recipient and
donor

are

identical

twins,

all

recipients

receiving

BMT

should

undergo

immunosuppressive therapy.

1.2

Allogeneic graft-versus-host disease
Graft-versus-host disease remains a major complication following allogeneic

BMT. In 1967, Billingham described three requirements for GVHD to take place: First,
the graft must contain immunologically competent cells (which are now known to be T
cells); second, the recipient must express tissue antigens that are not present in the
transplant donor; and third, the patient must be incapable of mounting an effective
response to eliminate the transplanted cells [23]. GVHD takes place when T cells in the
graft respond to HLA proteins on host cells and the frequency of this disease is directly
related to the degree of mismatch that exists between HLA proteins [24]. Reports show
that GVHD occurs in 25-60% of patients who receive BM from an HLA-identical related
donor and in 45-70% of recipients from matched unrelated donor [15, 25, 26]. As a
consequence, approximately 50% of patients who might benefit from BMT cannot find a
suitable match related or unrelated donor to be able to benefit from this therapeutic
option. Ferrara et al. has described the pathophysiology of GVHD as a multifaceted
process that occurs in three stages [17, 27]: (1) preconditioning regimens (i.e. high doses
of chemotherapy) results in damage to host tissues leading to increased proinflammatory
rmed inces, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1),
amplified expression of adhesion molecules and MHC antigens in target organs
(intestine, liver skin) [28-31] allowing the migration of effectors cells to the site of
inflammation; (2) recognition of alloantigens on host APC by donor T cells, results in T
5

cell proliferation, differentiation and secretion of TH1 cytokines (IFN-γ and IL-2); and (3)
effector cell activation (i.e. macrophages, natural killer cells, cytotoxic T lymphocytes)
that act in concert with the cytokines described above to cause further tissue injury.
Finally, it has been demonstrated that mature alloreactive T cells that contaminate the
marrow and which are responsible for the second stage of this disease are able to initiate
two forms of GVHD: acute and chronic [17].
In clinical GVHD, the acute phase is observed during the first 100 days posttransplant and is considered the major challenge of patients because of its high
association with morbidity and mortality [32]. This stage is associated with damage to the
liver (cholestatic hyperbilirubinaemia), skin and mucosa (maculopapular skin rash) and
gastrointestinal (GI) tract (nausea, anorexia, watery and/or bloody diarrhea and severe
abdominal pain) [26, 27]. The chronic phase normally occurs after 100 days and it
adversely influences long-term survival. In addition to the organs damaged by acute
GVHD, the chronic phase also affects nails, mouth, eyes, muscles, connective tissues,
lung, kidneys, heart, marrow and female genitalia [27, 33]. Severity of acute GVHD is
scored by the extent of involvement of the three main target organs (skin, liver and GI):
grades are I (mild), II (moderate), III (severe), and IV (very severe). Severe GVHD has
poor prognosis, with 25% long-term survival (5 years) for grade III disease and 5% for
grade IV [34]. The relationship between acute and chronic GVHD is controversial. While
some findings support the idea that the chronic phase is an extension of the acute stage
[35, 36], others suggest that they appear separately [37, 38]. Atkinson et al. reported that
acute and chronic are different diseases but share similar risk factors (HLA disparity,
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female → male transplant, recipient age, etc.) and that the major risk factor for chronic
GVHD is the prior occurrence of acute GVHD [36].
Mouse models have been important in the classification and understanding of the
processes underlying GVHD. Different effector cells have been associated with the
development of GVHD depending on the type of mismatch involved in the transplant.
When donor and recipient differ at MHC Class II, CD4+ T cells have been reported to be
the effector cells responsible for the disease process [21, 39]. Conversely, when donor
and recipient differ at MHC Class I, CD8+ T cells are associated with disease induction
[21, 40]. Meanwhile, the effector cells that cause GVHD in miHA mismatch models
depends on the combination of strains used [41]. When the type of TH immunity that was
involved in the development of GVHD was analyzed, acute GVHD was dominated by a
TH1 response while the T cell response during chronic GVHD is driven primarily by a
TH2 type, characterized by the production of IL-4 and IL-10 cytokines [42, 43] and the
production of autoantibodies [44]. Although the work is ongoing, recent studies within
the last year or so have demonstrated a role for TH17 immunity in the development of
GVHD [45, 46].
Many approaches have been used over the years to minimize GVHD following BMT.
One strategy includes T cell depletion (TCD) from the donor inoculum which has been
reported to decrease GVHD but this treatment has been associated with increased rates of
graft failure and relapse [25, 47, 48]. Reisner et al. demonstrated that depletion of T
cells, with soybean or peanut agglutination, from mouse bone marrow and spleen cells
suspensions resulted in successful reconstitution of lethally irradiated mice without
complications due to GVHD [47]. In 1981, Valera et al. reported that ex vivo depletion of
7

T cells, with the use of monoclonal antibody against Thy 1.2, in a murine transplant
model receiving MHC-mismatched BM prevented GVHD, indicating a role for T cells in
this disease [48]. Due to the success of studies in animal models, human clinical trials
using various methods of TCD have been used [25, 49]. These trials confirmed the low
incidence of GVHD observed in animal models but was also accompanied by other
limitations (i.e. graft rejection, delayed immune reconstitution, increased rate of disease
relapse) that did not improve overall survival. Another approach that has been used to
control GVHD after BMT includes the use of immunosuppressive drugs such as
cyclosporine A (CsA), prednisone, and methotrexate. These agents by themselves
typically fail to completely diminish GVHD but therapies using drug combination has led
to better prognosis [50, 51]. One problem is their lack of specificity since they affect
many immune responses indiscriminately, causing the patients to be more susceptible to
opportunistic infections as well as causing toxicity to several organs [52].
Graft-versus-host disease remains the major limitation of allogeneic BMT since it
causes significant morbidity and mortality in patients undergoing such treatment [32].
The efficacy of allogeneic BMT has been accredited to an allogeneic graft-versus-tumor
(GVT) response that is associated with the development of GVHD [53]. However,
because of the toxicities and risks associated with this procedure only a few patients can
benefit from allogeneic BMT. Meanwhile, autologous BMT is less toxic and does not
lead to GVHD development since the use of autologous stem cells eliminates donor antirecipient alloreactivity. Nonetheless, an increase in relapse is associated with this method,
presumably due to the lack of an allogeneic GVT response [32], suggesting that T cells
present in the donor marrow graft are necessary to mediate this response. Thus, the
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manipulation of the system during the post-transplantation period following autologous
BMT in order to induce a GVT response, could be beneficial to patients without the
allogeneic BMT limitations.

1.3

Syngeneic graft-versus-host disease (SGVHD)
Syngeneic GVHD was described by Glazier et al. as a GVHD-like syndrome that

developed in rats following syngeneic BMT and cyclosporine A (CsA) treatment [16]. In
the rat SGVHD model pathology was observed in the intestine, liver, skin and tongue that
was similar to that observed in allogeneic GVHD. Due to these similarities in pathology
and the use of BMT, this disease was termed CsA-induced syngeneic GVHD. Further
studies revealed that upon cessation of CsA therapy, an acute phase occurred during rat
SGVHD that was characterized by the infiltration of lymphocytes, mainly CD8+ T cells
and destruction to the epithelium in target organs. This response was followed by a
chronic phase that consisted of further damage to the epidermis (fibrosis and
scleroderma) and dominated by CD4+ T cells [54].
Syngeneic GVHD can be induced in mice by reconstituting lethally irradiated
animals with syngeneic BM cells followed by a 21 day treatment with
immunosuppressive agent cyclosporine A (CsA) [55]. Clinical symptoms of the disease,
which include weight loss and diarrhea, appear 2 to 3 weeks after cessation of CsA
therapy. Similar to acute GVHD in murine models, SGVHD-associated inflammation
occurs primarily in the colon and liver [55]. Three conditions are required for the
induction and development of SGVHD: First, the recipient must have a thymus. Second,
the thymus must be in the field of irradiation. Previous work has shown that
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thymectomized animals do not develop SGVHD [56]. Third, animals have to be
irradiated for optimal induction of the disease. Disease does not develop in normal
animals treated with CsA alone [57] or following adoptive transfer of T cells from
diseased animals into secondary recipients that are not irradiated [57, 58]. Finally, CsA
therapy is required for disease induction since animals undergoing syngeneic BMT that
do not receive CsA treatment have been shown not to develop SGVHD [16].
As mentioned above, CsA is an immunosuppressive drug that has been used
clinically [59] and experimentally [18] to prevent graft rejection following solid organ
transplantation

and

to

prevent

GVHD

following

allogeneic

BMT.

This

immunosuppressive drug is derived from Tolypocladium inflatum, a soil fungus. It blocks
T-cell proliferation by inhibiting the phosphate activity of calcineurin, a Ca2+-activated
enzyme. Calcineurin is an important phosphatase involved in signaling transmission from
the T cell receptor (TCR) to the nucleus. Upon its activation, calcineurin
dephosphorylates nuclear factor of activated T cells (NFAT), rendering it active and
capable of migrating into the nucleus to induce the transcription of NFAT-dependent
genes. CsA inhibition of the calcineurin signaling pathway in T cells ultimately inhibits
the clonal expansion of activated T cells [2, 60](see Figure 1.1). CsA has various
biological effects on T cells, including the downregulation of proinflammatory cytokines
[61, 62]. Studies have shown that CsA can impair T cell function by blocking the
production of IL-2 in activated T lymphocytes, observed by decreased levels of IL-2
mRNA [63, 64]. In addition, in vitro studies have shown that CsA can reduce the
production of IL-15 and TNF-α through the upregulation of IL-10 in cell culture of
rheumatoid synovial fibroblasts [62]. And inhibition of IL-15-induced IL-17 production
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in CD4+ T cells have been reported after CsA treatment [61]. Long-term treatment with
CsA results in toxicities in the kidney and liver. CsA therapy has been shown to cause
tubular injury, with interstitial cell proliferation, extracellular matrix deposition and the
infiltration of macrophages into the interstitium of the kidney [65]. CsA treatment has
also been reported to affect liver pathology by causing hepatocyte damage, necrosis [66,
67] and cholestasis [68]. CsA induced hepatotoxicity includes impairment of antioxidant
enzymes [66, 67] as well as disorganization of the canalicular bile salt export pump
transporter mechanism [69]. Finally, CsA treatment has been shown to affect the thymus
and consequently T cell maturation [70]. There is evidence that CsA therapy in animals
leads to damages of the thymic architecture and the medullary region [71] that may affect
negative selection of immature thymocytes and has been proposed to mediate the
development of SGVHD following lethal irradiation, syngeneic BMT and treatment with
CsA [70].

1.4

Role of T cells in SGVHD
The role of T cells as an effector cell population has been well established in the

rat model of SGVHD. Various studies have demonstrated the role of CD4+ as well as
CD8+ T cells in the induction and development of rat SGVHD [56, 72]. The disease in
the rat model is characterized by an early acute phase mediated by CD4-CD8+ T cells,
that takes place within the first week after the cessation of CsA treatment, followed by a
chronic phase that is dominated by double positive T cells (CD4+CD8+) [54]. Finally, rat
SGVHD can be adoptively transferred into secondary irradiated animals by T cells
isolated from diseased animals [57, 72].
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The major effector cells in rat SGVHD were originally described as cytotoxic
CD8+ T lymphocytes that were specific for MHC class II antigens [73]. It is interesting
that the CD8+ autoreactive T cells promiscuously recognize MHC class II molecules [74].
This observed association is aberrant in that CD8+ T cells typically recognize antigen in
the context of MHC class I molecules. It was later shown that these effector cells were
specific for the class II-associated invariant chain peptide CLIP [73]. This peptide is
generated during the trafficking of MHC class II to the surface of the cell. The invariant
chain binds to the newly synthesized MHC class II molecules and blocks the binding of
peptides and unfolded proteins in the endoplasmic reticulum and during the transport of
the MHC class II molecule into acidified endocytic vesicles. In these vesicles, proteases
cleave the invariant chain, leaving the CLIP peptide attached to the binding groove of the
MHC class II molecule. Endocytic antigens (pathogens and their proteins) are degraded
to peptides in the endosome but cannot bind to MHC class II molecules that are occupied
by the CLIP peptide. Once CLIP is bound to the MHC class II molecule, it cannot bind
other peptides thus inhibiting their upload and delivery to cell surface were they can be
presented to effector cells [2, 75]. For CLIP to be removed from the binding groove of
the MHC class II molecule it requires the action of the MHC like-molecule, DM (HLADM for human and H-2M for mouse), which is encoded in the MHC locus and resides in
the endosome. DM catalyses the dissociation of CLIP and stabilizes the MHC class II
molecule so it can interact with antigenic peptides in the endosome. Once a stable
peptide/MHC class II complex forms, DM disassociates and the complex transits to the
cell surface of MHC class II expressing cells [75]. Further characterization revealed that
the reactivity of CD8+ autoreactive T cells from SGVHD rats with MHC class II
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molecules bearing CLIP was based on the specific interaction of the N-terminal flanking
region of CLIP/MHC class II and the Vβ segment of the TCR to initiate a pathogenic
immune response. Fischer et al. demonstrated that the CD8+ autoreactive T cell
population in rat SGVHD predominantly expresses Vβ 8.3/8.5 TCR and adoptive transfer
of these cells (Vβ 8.5+CD8+ T cells) could promote SGVHD in secondary recipients [76].
However, clonal analysis of these regions revealed that not only the N-terminal flanking
region on CLIP could stimulate T cells but that the C-terminal region presented in the
context of class II could also activate SGVHD T cells. However, only the cells that were
specific for the N-terminal region of CLIP were pathogenic in vivo, while clones
requiring the C-terminal region were nonpathogenic [74]. It is interesting to note that the
pathogenic CLIP-reactive T cell clones have the ability to produce TH1 cytokines (IL-2
and IFN-γ), that mediate the acute phase of the disease, while the nonpathogenic Cterminal-reactive clones produced TH2 cytokines (IL-4 and IL-10), that are associated
with the chronic disease stage [77]. These studies demonstrated that an autoreactive,
pathogenic CD8+ T cell response was associated with the generation of rat SGVHD.
However, while the induction protocol and tissue pathology were similar between the rat
and mouse models of SGVHD, data will be presented demonstrating that the effector
mechanisms underlying the murine model of SGVHD appear to be very different from
that observed in the the rat model of this inducible disease.
Immunohistochemical (IHC) analysis has demonstrated an increased presence of
CD4+ and CD8+ T cells in the colonic lesions of mice with SGVHD [78]. However,
murine SGVHD appear not to be mediated by CD8+ T cells, since cytotoxic T cell
responses were not demonstrated in this disease model [79]. Recently, the role of CD4+ T
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cells in the development of murine SGVHD was clearly established [58, 78]. First, as
described above, IHC analysis revealed an increased presence of CD4+ T cells in the
SGVHD colon. Upon isolation and characterization of immune cells from the colons of
SGVHD mice, it was shown that increased numbers of CD4+ T cells were present in the
colons of diseased animals compared to BMT control and normal mice [78]. The
percentage and numbers of CD8+ T cells did not change between the diseased and control
animals. To determine if the increase in CD4+ T cells in the colons of SGVHD mice was
functional, in vivo T cell depletion studies were employed. The use of a monoclonal
antibody (mAb) cocktail against T cells during the post-CsA period failed to inhibit
disease [80] and subsequent analysis revealed that antibody treatment was able to remove
peripheral CD4+ T cells but not colonic T cells [78]. Thus, Ab therapy after cessation of
CsA therapy failed to eliminate T cells from the colons of treated animals and did not
alter disease induction. Expanding on these studies, specific mAb against CD4+ or CD8+
T cells were utilized following myeloablative conditioning and during the 21 days of CsA
therapy period to inhibit T cell migration into the gut and to determine the role of these T
cell subsets in the development of SGVHD. Treatment during this period specifically
removed CD4+ or CD8+ by day 21 post-BMT. Depletion of CD4+ T cells, but not CD8+
cells, significantly reduced the induction of clinical symptoms as well as pathology
associated with murine SGVHD [78]. These findings were supported by additional
experiments demonstrating that CD4+ T cells isolated from SGVHD mice were capable
of inducing disease when adoptively transferred into irradiated secondary recipients [58].
Taken together, these studies demonstrated that the presence of CD4+ T cells in the
colons of CsA-treated mice during the induction period is critical for disease
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development. In addition, Bryson et al. [58] have shown that CD4+ T cells isolated from
the spleen and mesenteric lymph nodes from SGVHD had increased proliferative
responses against dendritic cells (DC) pulsed with a bacterial lysate prepared from the
cecum of normal mice. CD4+ T cells from SGVHD mice did not respond against
syngeneic/self APC (unpulsed DC or splenic APC), or DC pulsed with self epithelial
antigens, nominal protein antigens or food-derived antigens, demonstrating a specificity
for bacterial antigens. With the similarity between SGVHD-intestinal inflammation and
murine models of colitis and the dependency of colitis models on bacterial specific T
cells [81, 82], we hypothesized that bacterial-specific CD4+ T cells may mediate the
induction of murine SGVHD. Thus, based on the phenotype of the major effector cells,
as well as, putative antigen specificity, it is clear that while SGVHD is induced via
similar protocols, the T cell response is demonstrably different in the rat and mouse.

1.5

Proinflammatory mediators and SGVHD
Previous studies demonstrated significantly higher levels of mRNA for the TH1

cytokines IL-12, interferon-γ (IFN-γ) and TNF-α in target organs of mice that had
developed SGVHD. In vivo depletion of IL-12 [80], as well as TNF-α [83], inhibited the
development of the disease suggesting a role for TH1 cytokines in the development of
murine SGVHD [80]. The role of macrophages in this inducible disease was documented
by Flanagan et al. [83]. Activated macrophages were present in SGVHD mice. These
animals were more responsive to sublethal doses of LPS relative to control animals. As
macrophages are a major source of IL-12 and TNF-α and are responsive to LPS and other
bacterial products through interaction with toll-like receptors [84] it was concluded that
activated macrophages play a major role in the development of SGVHD. Thus, activation
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of macrophages could lead to an increased release of proinflammatory cytokines,
resulting in enhanced production of IL-12 and TNF-α, cytokines which were shown to
contribute to the development of murine SGVHD [80, 83].

1.6

Oxidative Stress and SGVHD
Both radiation and CsA are required for the development of SGVHD [57, 85] and

participate in the induction of oxidative stress [65, 86-88]. Radiation allows for the
elimination of regulatory cells that are present in normal mice and are capable of
modulating the induction as well as the adoptive transfer of SGVHD [58, 73]. Irradiation
is also required to prolong the alterations in thymic architecture induced by CsA
treatment which has been proposed in the rat model to alter thymocyte maturation
resulting in the generation of self-reactive T cells [71]. Finally, it has been demonstrated
that cell killing by ionizing radiation is mediated primarily through the induction of
oxidative stress [89-91]. Several toxicities are also associated with the use of CsA
immunosuppression. CsA-associated side effects include damage to the vascular
endothelium via the production of reactive oxygen species (ROS) [86-88, 92].
Administration of CsA to rats has been shown to cause overproduction of ROS, measured
by increased levels of 2’,7’-dichlorofluroscein (DCF) and malondialdehyde (MDA) as
well as increased RNS shown by elevated iNOS and nitrotyrosine levels [87, 88]. Also,
CsA-induced oxidative stress has been shown to activate some transcriptional factors,
such as nuclear factor kappa B (NF-kB), leading to the activation of gene transcription of
proinflammatroy molecules, including ROS/RNS mediators [93].
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In addition to the generation of ROS by conditioning agents, oxidative signals can
also be induced by cytokines. Tumor necrosis factor-α, is a prime example and is
regulated transcriptionally by NF-κB, which is a ubiquitous transcription factor
implicated in the induction of many cytokines and adhesion molecules involved in
immune and inflammatory responses [27, 94]. The NF-κB family of transcription factors
is composed of five members: p65 (REL-A), REL-B, cytoplasmic c-REL, p50 and p52
which function as homo- or heterodimers. NF-κB dimers are sequestered in the
cytoplasm in an inactive form which is bound to the inhibitor molecule IκB. Tumor
necrosis factor-α signaling mediates the phosphorylation of IκB via a kinase complex
leading to the polyubiquitination and proteosome-mediated degradation of the inhibitor
and allowing for the release of the NF-κB factors. Free NF-κB dimers can then
translocate to the nucleus and activate gene transcription of proinflammatory molecules
[95, 96].
The development of SGVHD is a multi step process resulting from the
cooperative interaction of various effector cell populations, including NK cells [80], T
cells [78, 97] and macrophages [83], along with TH1 cytokines that result as a
consequence of the preconditioning regimes during the induction the disease [80, 83].
However, the mechanism of action of these proinflammatory cytokines in SGVHD
remains unclear. A possible mechanism could be via their stimulation of oxidative stress,
including the production of nitric oxide (NO) [98]. Nitric oxide is a ubiquitous molecule
needed for normal physiologic functions but it is also associated with several pathologic
diseases including GHVD [98-102]. Nitric oxide is generated from L-arginine through an
oxidation reaction that is catalyzed by NO synthase (NOS)(see Figure 1.2). It can be
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produced via constitutive and inducible forms of the NO synthase (iNOS, NOS2)
enzyme. The constitutively expressed forms are found in vascular endothelial cells
(eNOS, NOS-3) or in neuronal cells (nNOS, NOS-1). The inducible form of NOS (iNOS)
can be expressed in many cell types including macrophages, neutrophils, endothelial cells
and hepatocytes; it also has immunosuppressive properties that may play a role in the
downregulation of immune responses [98]. It is known that activated macrophages have
the ability to produce large amounts of nitric oxide (NO), via the iNOS (NOS2) enzyme
[103] . Since studies revealed a role for macrophages in SGVHD, due to IL-12 secretion,
and they are known to produce NO, the contribution of this inflammatory mediator to the
development of murine SGVHD was studied during the active disease period (after
cessation of CsA therapy). The functional role for NO was determined by the treatment
of mice with the iNOS inhibitor aminoguanidine (AG) [104]. Inhibition of iNOS resulted
in the abrogation of clinical symptoms, tissue pathology and cytokine (IL-12 and IFN-γ)
levels associated with the development SGVHD [100]. Nitric oxide has also been studied
in animal models of allogeneic GVHD. Inhibition of iNOS also resulted in reduced
development of pathophysiology (i.e. tissue injury, intestinal pathology, reduced
lethality) associated with allogeneic GVHD [104, 105]. Hongo et al. studied the role of
NO during the early stages of GVHD induction (days -2 up to 14 post-BMT) and
concluded that NO had a protective effect during this period since enhanced mortality
was observed in mice when NO was inhibited by treatment with AG [106]. Similar
results were obtained by Drobyski et al. in which inhibition of iNOS, with the
administration of NG-methyl-L-arginine (L-NMA), after allogeneic BMT, resulted in
significant decreased survival, likely due to decreased engraftment [98].
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By itself, NO is a weak free radical but in combination with other ROS, like
superoxide (O2-), it can result in the formation of peroxynitrite (OONO-), a very toxic and
reactive product capable of mediating several cytotoxic processes [107](see Figure 1.3).
Data presented in this dissertation will address the involvement of oxidative stress in the
development of murine SGVHD and will be discussed in Chapter 3.

1.7

Lymphocyte homing to inflammatory sites
Homing of naïve lymphocytes from their site of origin, either bone marrow or

thymus, into lymph nodes and peripheral tissues is governed by their lymphocyte
trafficking properties, which include tissue-specific adhesion and chemokine interactions
[2, 108-113]. Migration into the inflamed gut requires lymphocyte trafficking through the
mesenteric lymph nodes (MLN), an important site of the mucosal immune system [114].
Naïve T cells enter the MLN via high endothelial venules (HEV) and are able to
encounter foreign antigens by their interaction with dendritic cells (DC) that resided in
the intestinal tract and have processed gut-associated antigens, and transported them back
to the MLN. As a consequence, these lymphocytes interact with these gut-antigen
presenting DC, become activated and express surface markers (i.e. L-selectin, α4β7) that
change the migratory behavior of these activated effector cells. This acquired gut-homing
phenotype enables them to reach the site of inflammation where they can exert their
effect [2, 114, 115]. Proinflammatory chemokines, released by the tissue along with their
corresponding receptors, found on active lymphocytes form an important axis that directs
lymphocytes to the gut. Specific chemokines and their receptors, including CCL20,
CCL5, CCR5, CCR6 among others, have been previously associated with inflamed
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intestines observed in inflammatory bowel diseases (IBD) as well as murine models of
colitis [111, 112].
The recruitment of leukocytes from the vascular compartment into the
extravascular space is crucial for the development of inflammatory responses. This
movement involves cell adhesion interactions that are regulated by several ligands known
as cell adhesion molecules (CAM) which are expressed in the surface of endothelial cells
and leukocytes [110, 113, 116, 117]. Mucosal vascular addressins are tissue-specific
endothelial cell adhesion molecules for circulating lymphocytes. They are expressed on
the surface of vascular endothelial cells and serve as receptors to which ligands expressed
on the surface of activated lymphocytes bind, thus allowing leukocyte homing to specific
tissues [118]. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is an example
of one of these vascular addressins that is expressed in mucosal endothelium lining blood
vessels and serves to guide the entry of lymphocytes into mucosal lymphoid tissues such
as the gut. MAdCAM-1 plays a critical role in mucosal immunity and is up-regulated
during inflammation in the gut [116, 117]. It binds to integrin α4β7 expressed on the
surface of activated T lymphocytes allowing their migration into the gut where they can
initiate an inflammatory response [2, 116, 117]. It has been shown that lymphocytes
expressing α4β7 migrate in a selective manner to sites of MAdCAM-1 expression [109].
Other examples of adhesion molecules include intercellular adhesion molecule-1 (ICAM1) and vascular adhesion molecule-1 (VCAM-1) which are both expressed on the
endothelium and bind to integrins expressed on the surface of activated lymphocytes.
Lymphocyte function-associated antigen-1 (LFA-1) is the ligand for ICAM-1 and has a
major role in T cell activation and migration of both naïve and effector T cells out of the
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blood. VCAM-1 binds to integrin α4β1, also known as VLA-4, thus allowing for the
extravasation of effector T cells [2, 116]. It has been reported that TNF-α, and other
proinflammatory mediators, can induce VCAM-1, ICAM-1 [119] and MAdCAM-1 upon
inflammatory responses [120]. Oxidative stress induced by immune responses as a
consequence of irradiation treatment and/or cytokine production can also induce CAM
expression [121].
The interaction of blood lymphocytes with the endothelium involves multiple
steps that account for their specificity. First, selectins on the T lymphocyte cells bind to
sulfated carbohydrates on proteins such as vascular addressins (i.e. GlyCAM, ICAM-1,
MAdCAM-1) that are expressed on endothelial cells. This allows for lymphocyte contact
and weak interaction with the endothelium which initiates rolling of the lymphocyte
along the endothelium surface. This step is crucial to initiate the cascade that leads to
stronger interactions to allow for lymphocyte migration into the tissue. The second step
consists of the actions of activating factors (i.e. chemokines), found in the environment,
that bind to proteoglycan molecules on the endothelium walls and to receptors in the T
lymphocyte cell, triggering rapid intracellular signaling in the leukocyte. This interaction
leads to the activation of preexisting cell surface integrins (i.e. LFA-1, β7, α4) on the T
cell that increases its affinity for cell adhesion molecule receptors (i.e. ICAM-1,
MAdCAM-1, VCAM-1) which are expressed on endothelial cells, mediating firm arrest
of the cell on the vessel wall. The interaction between receptor and counterligand allows
for the fourth step known as diapedesis/extravasation in which the lymphocyte migrates
through the vessel wall into the tissue [2](see Figure 1.4). The expression of these
vascular addressin on the endothelium serves as a mark point to signal the presence of
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infection attracting effector cells to the site of inflammation. Their interaction with
integrins expressed on activated lymphocytes allows for the entry, in large numbers, of
these effector cells into the infected tissue where they can conduct an inflammatory
response. As increased numbers of CD4+ T cells were observed in the colon of CsAtreated, BMT mice at the end of the SGVHD induction period, and the migration of these
cells to the colon during this period was shown to be essential for the development of this
disease [78], the data presented in Chapter 4 will examine the role of T cell homing into
the gut at the early stages after BMT in the development of SGVHD.
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Figure 1.1 CsA inhibition of the calcineurin signaling pathway in T cells
Adapted from Steinbach et al. [122]

Figure 1.1 CsA inhibition of the calcineurin signaling pathway in T cells. Activation of
T cell receptor (TCR) triggers increases in Ca2+ which activates calmodulin and allows its
binding to calcineurin. The calcineurin catalytic subunit (A), when bound to the
regulatory subunit (B) and calmodulin–Ca2+ complex, dephosphorylates nuclear factor of
activated T-cells (NF-AT) in the cytoplasm, leading to nuclear migration of this
transcription factor and the subsequent activation of various cellular processes. The
dephosphorylation of NF-AT is inhibited by cyclosporine A (CsA) and FK506.
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Figure 1.2 Nitric oxide generation from L-arginine oxidation
Adapted from Vallance et al. [123]

Figure 1.2 Nitric oxide generation from L-arginine oxidation. For enzymatic activity,
nitric oxide synthase (NOS) enzymes must dimerize and bind the cofactors
tetrahydrobiopterin (BH4), haem, flavin mononucleotide (FMN) and flavin adenine
dinucleotide (FAD). On binding calmodulin (CAL), the active enzyme catalyses the
oxidation of L-arginine to citrulline and nitric oxide (NO) and requires molecular oxygen
and NADPH as co-substrates. Each NOS dimer coordinates a single zinc (Zn) atom.
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Figure 1.3 Generation and detoxification of ROS/RNS
Adapted from Griendling et al. [124]

Lipid peroxidation
Protein oxidation/nitration
Inactivation of enzymes
DNA strand break/apoptosis
Decreased NO bioavailability

Figure 1.3 Generation and detoxification of ROS/RNS. Oxidases convert oxygen to
superoxide (•O2⎯) which can react rapidly with nitric oxide (NO•) to form peroxynitrite
(ONOO⎯) and cause downstream cellular damages. •O2⎯ can also be dismutated to
hydrogen peroxide (H2O2) by superoxide dismutase (SOD). H2O2 can be converted to
H2O by catalase or glutathione peroxidase (GSH-Px) or to hydroxyl radical (•OH) after
reaction with Fe2+.
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Figure 1.4 Attachment of T cells to the endothelium and extravasation
Adapted from Kunkel et al. [125]

Figure 1.4 Attachment of T cells to the endothelium and extravasation. Integrins present
on the surface of T cells mediate adhesion to the endothelium via their interaction with
CAM. The multiple steps involved in T cells attachment to the endothelium includes: (1)
tethering, (2) rolling, (3) adhesion and (4) diapedesis/extravasation.
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CHAPTER TWO: MATERIAL AND METHODS
2.1

Mice
C3H/HeN mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN)

at 20–21 days of age and were used within 1 week of arrival. The mice were given
acidified water and fed autoclaved lab food ad libitum and were housed in sterile
microisolator cages (Lab Products, Maywood, NJ). The animal used protocols were
reviewed and approved by the University of Kentucky Institutional Animal Use and Care
Committee.

2.2

Induction of SGVHD
Bone marrow (BM) was isolated from the femurs and tibias of syngeneic age-

matched mice. The donor BM suspensions were prepared in RPMI 1640 (Cellgro,
Herndon, VA) supplemented with 5ml of penicillin/streptomycin/glutamine (100X;
(Gibco-Invitrogen, Grand Island, NY)(see Appendix A for solution preparation). The
resulting cell suspensions were resuspended in cytotoxic medium (RPMI 1640 containing
penicillin/streptomycin/glutamine and 0.3% BSA Fraction V (Gibco-Invitrogen)) to a
final concentration of 5 x 107 cells/ml. BM cells were treated with monoclonal antibody
(mAb) against Thy1.2 (HO-13-4, 1:20; American Type Culture Collection, ATCC No.
TIB-99, Rockville, MD) to deplete Thy1+ cells, for 60 minutes on ice. Anti-Thy1.2treated BM cells were then washed three times with cytotoxic medium and treated with a
1:10 dilution of Low Tox-M rabbit complement (Cedarlane Laboratories, Westbury, NY)
at a concentration of 5 x 107 cells/ml for 1 hour in 37°C water bath. After incubation,
cells were washed three times with cytotoxic medium. Cell count was performed by
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diluting cells 1:100 in cytotoxic medium with the adition of 5% acetic acid (Baxter;
Stephens Scientific, Riverdale NJ, USA) then counted on a hemacytometer. The cell
viability was determined by trypan blue exclusion. Removal of donor BM Thy1+ cells is
required for disease development because in the presence of these autoregulatory cells
development of SGVHD is reduced or inhibited depending on the strain of mice used
[97]. Recipient mice were lethally irradiated with 900 cGy in a Mark I

137

Cs irradiator

(J.L. Shepard and Associates, Glendale, CA) 4-6 hours before transplant. Irradiated mice
were reconstituted with 5 x 106 T cell-depleted BM cells (ATBM) intravenously (i.v.) in
0.1 ml PBS via tail vein injection. Beginning on the day of transplantation, groups of
mice were injected intraperitoneally (i.p.) daily for 21 days with 0.1 ml of either 15
mg/kg CsA in the diluent olive oil (Sigma-Aldrich, St. Louis, MO) or diluent alone
(Figure 2.1). CsA was purchased through the Division of Laboratory Animal Resources,
University of Kentucky.

2.3

Evaluation of SGVHD
Following cessation of CsA, the animals were weighed three times per week and

observed for clinical signs of the development of SGVHD (weight loss and diarrhea).
Animals that lost weight for three consecutive weighings and/or diarrhea or mortality
were considered as positive for the induction of SGVHD. In general, by 2–3 weeks after
cessation of CsA therapy, clinical symptoms were evident (Figure 2.1) in approximately
80% of the treated animals. Tissue samples were taken from the animals at different
times during and post-CsA treatment. For histological evaluation of SGVHD, tissue
samples taken from euthanized animals were immediately placed in 10% buffered
formalin (Fisher Scientific, Atlanta, GA). Fixed tissues were embedded in paraffin, cut
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into 4 to 6 µm tissue sections, mounted on glass slides, and then stained with a standard
hematoxylin and eosin (H&E) procedure. All tissue sections were analyzed blind without
the knowledge of the treatment category of the animal and graded for inflammation
caused by SGVHD using a previously published grading scale [79] (Table 2.1).

2.4

In vivo treatment with the antioxidant MnTBAP
Mice were lethally irradiated, reconstituted with syngeneic ATBM and treated

with either diluent or CsA as described. Treatment with MnTBAP was performed during
or post-CsA therapy (Figure 2.2). MnTBAP reconstitution was performed following the
manufacturer’s instructions (Axxora Life Sciences Inc., San Diego, CA.). The black
crystalline powder was dissolved in 1 ml 0.1M NaOH, then 9 ml of 1X PBS was added to
reach a final stock concentration of 5 mg/ml. The pH was adjusted to 7.4 and the solution
was filter sterilized using a 0.2 µm syringe filter. The MnTBAP stock was stored in the
dark at 4⁰C. For MnTBAP therapy during CsA period, treatment began two days prior to
BMT when mice were treated i.p. with 10 mg/kg or 20 mg/kg of MnTBAP ending at day
21 post-BMT. Twice a day dosing regimen was used based on the MnTBAP elimination
half-time of 9.5 hours [126]. For post-CsA treatment, twice daily (10 mg/kg) antioxidant
therapy began at day 21 post-BMT and was given for to 2-3 weeks. Treatment was
stopped when the majority of the CsA group (typically >80%) had developed SGVHD.
Following cessation of MnTBAP therapy, the animals were monitored for the
development of clinical symptoms of SGVHD as described.
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2.5

In vivo neutralization of TNF-α
To determine the effect of TNF-α on the induction of SGVHD, mice were treated

with soluble TNF Receptor-1 (sTNFR-1) (Amgen, Thousand Oaks, CA) during the CsA
treatment period (Figure 2.3). Four experimental groups were used in which mice
received either olive oil, CsA alone, sTNFR-1 only or CsA and sTNFR-1. Several
experiments were performed in which mice received sTNFR-1 beginning at different
time points: (1) Two days prior to bone marrow transplantation; (2) At day three postBMT or (3) One week (day 7) post-BMT. The mice received 100 µg of sTNFR-1 i.p.
beginning at the indicated times for 4 consecutive days and then every other day through
day 21 post-BMT. Moribund animals were euthanatized and counted as mortalities.
Animals were then monitored for clinical symptoms of SGVHD, as described previously.
At the end of each experiment tissue was collected and analyzed for changes in immune
parameters.

2.6

Isolation of peripheral lymphoid cells
At the indicated times after BMT, mice were euthanized by CO2 inhalation, the

spleens were removed and placed into Stomacher bags (Fischer Scientific) containing 10
ml 5% complete medium (RPMI 1640 containing penicillin/streptomycin/glutamine
(Gibco), 5% FBS (Atlanta Biologicals, Inc., Norcross, GA, USA) and 5mM 2mercaptoethanol (2-ME) (Sigma Chemical Co.)). The tissue was homogenized in a
Stomacher-80 (Fisher Scientific) to prepare single cell suspensions. The spleen cell
suspensions were then treated with 0.83% Tris-buffered ammonium chloride (NH4Cl),
pH 7.2, for 7 minutes at room temperature to lyse the red blood cells. Cells were then
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washed once with 5% complete medium and the resulting cell population was diluted in
0.04% trypan blue, counted on a hemacytometer and cell viability was determined by
trypan blue exclusion. Isolated lymphoid cells were then stained following flow
cytometry procedure described below.

2.7

Treatment of lymphocytes with DCFH-DA
Intracellular ROS were detected using the cellular marker 2’,7’-dichloro-

dihydrofluroscein diacetate (DCFH-DA) (Molecular Probes, Eugene, OR) following the
method of Saito et al. with a slight modification [127]. Briefly, the lymphoid cells were
isolated (2 x 106 cells/ml), washed once in 5% complete RPMI then resuspended in
phosphate-buffered saline (PBS). The cells were incubated with DCFH-DA at a final
concentration of 5 μM for 30 minutes at 37⁰C. Following incubation, the cells were
washed twice in PBS and stained for surface markers following the flow cytometry
method described below.

2.8

Isolation of immune cells from the colon
Intraepithelial lymphocytes (IEL) and lamina propia lymphocytes (LPL) were

isolated according to a modification of the method of Lefrancois and Lycke [128]. Colons
were removed from euthanatized mice at different times post- BMT and placed in Petri
dishs containing cold calcium and magnesium free (CMF) HBSS (Ca2+ and Mg2+ free,
100 mM HEPES (Sigma-Aldrich), 250 mM sodium bicarbonate (Fisher Scientific,
Pittsburgh, PA), and 2% FBS (HyClone, Logan, UT)). The colons were cleaned by
removing debris and all fecal matter. Tissue was cut open longitudinally and then
laterally into ~0.5 cm pieces. Colon pieces were transferred into 50 ml conical tube
31

containing 40 ml cold CMF and kept on ice. Individual colons were pooled within the
experimental groups and washed three times in cold CMF. Colon pieces were transferred
into a sterile 125 ml Erlenmeyer flask and treated with 20 ml of 37⁰C CMF solution
containing 1 mM dithiothreitol (DTT) (Research Products International, Mt. Prospect, IL)
and 1 mM ethylenediamine tetraacetic acid (EDTA) (Sigma-Aldrich) and placed on a
shaker for 30 minutes in a 37⁰C warm room. This step allows detachment of the epithelial
cell layer. After incubation, contents of each flask were transferred to 50 ml conical
tubes. The tubes then were vortexed for 15 seconds and the supernatant containing cells
was collected. CMF-DTT-EDTA was added to the tissue and the step was repeated twice
combining the supernatant of both collections. The cell containing supernatant represents
the epithelial fraction and contains the IEL. Tubes containing supernatant were
centrifuged at 2000 rpm for 10 minutes. The supernatant was discarded and the cell pellet
was washed once with 5% complete medium. The IEL were resuspended in 10 ml cold
10% complete medium (RPMI 1640 containing 10% FBS (Atlanta Biologicals, Inc.,)
penicillin/streptomycin/glutamine (Gibco), and 5 mM 2-ME (Sigma)) and kept on ice
while working with the LPL isolation. LPL suspensions were prepared by treating the deepithelialized intestinal tissue with 20 ml 10% medium containing 240U/ml collagenase
(Sigma) and 2U/ml DNaseI (Roche, IN, USA) on a shaker for 1 hour at 37⁰C. This
allows for further digestion of the tissue and the release of colonic LPL. Supernatant was
then collected into 50 ml conical tubes and the step repeated twice collecting both
supernatants containing the LPL. Tubes were then centrifuged at 2000 rpm for 10
minutes. The supernatant was discarded and the cell pellet was washed once with 5%
complete medium. The pellet containing the LPL was resuspended in 10 ml cold 10%
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complete medium and kept on ice. To enrich for T cells, the IEL and LPL suspensions
were passed over a 0.2-g nylon wool (Robbins Scientific, Sunnyvale, CA) column and
eluted with medium. The entire volume of eluate was collected in a 50 ml conical tube.
Tubes were centrifuged at 2000 rpm for 10 minutes and pellet resuspended in 8 ml cold
44% Percoll solution and kept on ice. First, 100% stock Percoll solution was made by
diluting 90 ml Percoll (GE Healthcare Bio-Sceinces AB, Uppsala Sweden) with 10 ml of
10X PBS. The appropriate volume of 100% Percoll solution was then added to 5%
complete medium to make a 44% and 67% Percoll solutions. Lymphocytes were isolated
by density percoll gradient centrifugation by overlaying the IEL and LPL in 44% Percoll
solution over 14 ml polystyrene tubes containing 5ml cold 67% Percoll solution. Tubes
were centrifuged at 1800 rpm for 30 minutes at room temperature. The cells in the
44/66% Percoll interface were collected and transferred into a 50 ml conical tube. After
collection the cells were washed once with cold 5% complete medium and resuspended
in 2 ml of 10% complete medium. The resulting cell population was counted using 0.04%
trypan blue exclusion and analyzed by flow cytometry, as described below.

2.9

Flow cytometry analysis
Isolated lymphoid cells (1 x 106) from the spleens and colons were placed into

12x75 mm polystyrene tubes (Fisher Scientific) used for flow cytometry analysis and
washed once using 2 ml of staining buffer (PBS containing 1% FCS and 0.1% NaN3).
The staining buffer was poured off the cell pellet, leaving approximately 100 µl buffer in
the tube. One µg Fc block, an antibody against CD16/CD32 (2.4G2; BD PharMingen,
San Diego, CA) was added to each tube to reduce non-specific staining and incubated for
15 minutes on ice. The appropriate labeled antibody (see Table 2.2) was added to the
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tube to a final concentration of 1µg/tube and incubated on ice for 30 minutes. After
incubation, the labeled cells were washed once with PBS containing 0.1% NaN3 (Sigma)
and fixed with 1% paraformaldehyde (Sigma). Staining was analyzed using a BD
Biosciences FACS Calibur flow cytometer (San Jose, CA) and 20,000-25,000 cells were
analyzed per sample.

2.10 Immunohistochemical staining
To perform immunohistochemistry, tissue was placed in plastic cryostat holder
(Sakura Tissue-Tek 4566, Cryomold Intermediate, Torrance CA, USA) embedded in
Tissue-Tek Optimal Cutting Temperature (OCT) compound (Sakura Finetek, Torrance
CA, USA), snap frozen in liquid nitrogen and stored in a -80⁰C freezer. Tissues were cut
into 10-µm tissue sections, using a cyostat microtome instrument (Microm HM 505N) at
-22⁰C, mounted on glass slides (Superfrost Plus Fisherbrand, Fisher Scientific, PA, USA)
and stored in a -20⁰C freezer. Usually 4-6 slides per tissue was cut with each slide
containing 2-3 tissue sections. At the time of staining, tissues were fixed in 3%
paraformaldehyde for 15 minutes and washed three times with PBS for 5 minutes each.
Slides were treated with blocking solution containing 2mg/ml normal donkey serum
(Jackson ImmunoResearch, West Grove, PA), 0.3% Triton X-100 in PBS for 30 minutes
at 4°C to block non-specific binding. All incubations were carried out in a dark
humidifying chamber (Tupperware container with wet paper towel inside) to prevent
drying. After draining the excess blocking solution, slides were randomly selected for
incubation with appropriate primary antibody (see Table 2.3) in PBS containing 2mg/ml
normal donkey serum and 0.3% Triton X-100 at 4⁰C overnight. After washing twice
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with PBS for 30 minutes, sections were incubated with corresponding secondary antibody
(see Table 2.3) for 1 h and then washed twice for 30 minutes. The MAdCAM staining
required a third antibody (Strep-PE) and the procedure was performed following the
exact same steps as staining with a secondary antibody. Control staining was performed
by omitting the primary antibody during the procedure to control for the specificity of the
primary antibody staining. Samples were visualized with a 100x objective and digitized
with an AxioCam HR Vision System (Carl Zeiss MicroImaging Inc., Thornwood, NY).
For each experiment, three to four animals were evaluated per experimental group and
from each organ 4-5 fields were analyzed.

2.11 Real Time Reverse Transcription-Polymerase Chain Reaction
(RT-PCR) for cytokine message
Total colon and liver RNA was isolated using Trizol reagent (Invitrogen, Grand
Island, NY). Briefly, samples were placed into RNA/DNAse-free 1.5 ml Eppendorf tubes
(VWR International, LLC, Batavia, IL), homogenized in 1 ml of Trizol by hand using
sample pestles (Reaserch Product International Corp., Mount Prospect, IL) and then
incubated for 5 minutes at room temperature. After the tissue was homogenized, 200 µl
of chloroform (Sigma St. Louis, MO) was added and the mixture was shaken vigorously
by hand and using a vortex mixer (Fisher Scientific). Samples were then centrifuged at
12,000 X g for 15 minutes at 4⁰C. The clear aqueous top layer was transferred into an
RNA/DNAse-free 1.5 ml Eppendorf tube (VWR International, LLC) and 500 µl of
isopropanol (Sigma) was added, to precipitate the RNA, and incubated for 10 minutes at
room temperature. Tubes were then centrifuged at 12,000 X g for 10 minutes. The
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supernatant was removed and the RNA pellet was washed with 1 ml 75% ethanol.
Samples were vortexed and centrifuged at 7,500 X g for 5 minutes and the supernatant
was discarded. The RNA pellet was resuspended in RNAse-free water, vortexed and
stored in a -80⁰C freezer. The amount of RNA present in each sample was quantified by
diluting 4 µl of RNA sample with 96µl of distilled water in a Quartz U.V. cuvette and
reading the absorbance at 260 and 280 nm using a SmartSpecTM 3000 Spectrophotometer
(Bio-Rad, USA). The A260:A280 ratio should be between 1.8-2.2 for pure RNA, values
below this ratio may indicate the presence of co-purified contaminants. One µg of RNA
from each group was reversed transcribed into cDNA using the Promega reverse
transcription system (Madison, WI)(see Table 2.4, Panel A for procedure). The PCR
reaction mixture was then prepared by combining 2.5 µl of cDNA with 10 µl of master
mix (see Table 2.4, Panel B) and 1 µM of appropriate primer (see Table 2.5). Real time
RT PCR was performed on a Roche Lightcycler (Roche Diagnostics, Indianapolis, IN)
and the amount of cytokine message was normalized to GAPDH and calculated by the
comparative CT method.

2.12 Measurement of serum NO
Circulating nitric oxide (NO) levels were determined using a Cayman Chemical
Nitrate/Nitrite Colorimetric Assay kit (Alexis Biochemicals, San Diego, CA). The
reagents in this kit use nitrate reductase to reduce serum nitrate (NO3⎯) to nitrite (NO2⎯).
To measure the production of NO during the induction of SGVHD (day 7-21 post-BMT),
normal, control, and CsA-treated mice were euthanized individually by CO2 inhalation,
and blood was obtained by cardiac puncture using a 25-gauge needle. The blood was
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allowed to clot overnight at 4⁰C and the serum was collected. The serum samples were
treated and assayed according to kit instructions. Briefly, samples were placed in 0.45
µM Ultrafree-MC Centrifugal Filter Devices (Millipore Corporation, Bedford, MA) and
centrifuged for 2 minutes at 12,000 g using a accuSpin™ Micro (Fisher Scinetific) to
remove interfering background absorbance attributable to proteins in the serum. After
preparation of serum samples, nitrate in the samples was reduced to nitrite by incubation
of 80 µl of sample with 10µl of Nitrate Reductase (Alexis Biochemicals) and 10 µl of
Enzyme Cofactor (Alexis Biochemicals) at room temperature for 3 hours. All analyses
were carried out in 96-well microtiter plates (Falcon, Becton Dickinson, Franklin Lakes,
NJ) in triplicates. A nitrate standard curve was prepared by mixing 0.9 ml of Assay
Buffer (Alexis Biochemicals) and 0.1 ml of reconstituted nitrite standard (in Assay
Buffer; Alexis Biochemicals). From this solution, eight dilutions were prepared to a final
nitrite concentration of 0, 5, 10, 15, 20, 25, 30 and 35 µM. The plate was set up as follow,
200 µl of Assay Buffer was added to blank wells, 100 µl of standard (for all eight
dilutions) or 100 µl of serum was added to appropiate wells. The nitrate concentration in
the samples was determined by the Griess reaction, by adding 50 µl of Griess reagent R1
(sulphanilamide; Alexis Biochemicals), immediately followed by 50 µl of Griess reagent
R2 (N-(1-Naphthyl) ethylenediamine; Alexis Biochemicals) to every well. The color was
then allowed to develop for 10 minutes, at room temperature, before the absorbance was
read at 540 nm using a Vmax microtiter plate spectrophotometer (Molecular Devices
Corporation, Menlo Park, CA). A standard curve comparison was used to obtain the
relative measurement of nitrite concentration for the serum samples.
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2.13 SG6 cell line
The SG6 cell line was established from peripheral lymphoid cells isolated from
SGVHD mice exhibiting clinical symptoms of disease (typically 60-80% of CsA-treated
animals). Animals were euthanized, the spleen and mesenteric lymph nodes were
removed and placed into stomacher bags containing 5% complete medium. After
homogenization, the single-cell suspensions of spleen and MLN were pooled and the
RBC were removed with Tris ammonium chloride as described. CD4+ T cells were
positively selected using CD4 (L3T4) mouse MicroBeads (MACS magnetic beads,
Miltenyl Biotech, Auburn, CA, USA) with the cells being selected on an AutoMACS
system (Miltenyl Biotech). The purity of the MACS-isolated donor cells was monitored
by flow cytometry and found to be > 92% CD4+ T cells. Purified CD4+ T cells (1-2 x
106), resuspended in 10% complete medium, were cultured in 24-well, flat-bottomed
microtiter plates with 2 x 106 (2000cGy) irradiated cecal antigen-pulsed spleenic APC.
The cecal antigen was prepared according to the procedure described by Cong et al. [81].
Briefly, the ceca were removed from animals and placed in a Petri dish containing PBS.
The cecal contents were collected by low-speed centrifugation and were resuspended in
PBS containing DNase I (10 µg/ml) (Sigma-Aldrich). Glass beads equal to 1/5th the
volume of the material in the tube were added and the preparation was sonicated for 5
min (15 s on, 15 s off) in a Fisher 550 Dismembrator (Thermo Fisher, Waltham, MA,
USA). After sonication, the antigen preparation was centrifuged for 15 min at 10,000 rpm
in a Fisher AccuSpin microcentrifuge (Thermo Fisher) to remove debris. The supernatant
was removed, filter sterilized, and analyzed for protein content by Bio-Rad assay
(Hercules, CA, USA). Spleen cells isolated from normal C3H/HeN mice were cultured
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overnight with 200µg cecal antigens, washed, irradiated (2000 cGy) and utilized as
described. After 8-10 days of culture the cells were harvested over lympholyte M
(Atlanta Biologicals). The viable cells were counted and restimulated as described.

2.14 Determination of Protein content using Bio-Rad assay
Protein levels of cecal Ag preparation was measured by Bio-Rad assay following
the standard protocol of the manufacturer. The Bio-Rad Dye reagent was prepared by
diluting 1 part Dye Reagent Concentrate with 4 parts of distilled, deionized (DDI) water.
The reagent was filtered using a Watman#1 paper to remove particulates. Dilutions were
prepared for the bovine γ-globulin protein standard (1.38 mg/ml) and the sample as
follow: four dilutions (690 µg/ml, 345 µg/ml, 173 µg/ml and 86.2 µg/ml) of the protein
standard and eight dilutions (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256) of the cecal
Ag preparation. One hundred (100) μl of each standard and sample solution was added
into a glass test tube. Five ml of the diluted dye reagent was added to each tube and and
the tubes were vortexed. The mixture was incubated at room temperature for 5 minutes.
After incubation, the absorbance was measured at 595 nm using a SmartSpecTM 3000
Spectrophotometer (Bio-Rad). A standard curve comparison was used to obtain the
relative measurement of protein concentration.
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2.15 Labeling of SG6 cells with (CFSE)
Cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) according
to the manufacturer’s instructions (CellTrace™ CFSE Cell Proliferation Kit, Invitrogen,
Eugene OR). Briefly, a 5 mM CellTrace™ CFSE stock solution was prepared by the
addition of 18µl of DMSO (Sigma) to a vial of CFSE. SG6 cells were labeled by
incubating 5 x 106 cells with 2.5 µM CFSE in PBS for 6 min at 37⁰C. After incubation,
the cells were washed once with 10% complete medium (RPMI 1640 containing
penicillin/streptomycin/ glutamine and 10% FBS (Atlanta Biologicals, Inc., Norcross,
GA, USA)). The cell pellet was diluted with 5 volumes of complete medium and the cells
were further incubated for 15 minutes at 37°C to remove excess dye. The cells were
washed with complete medium and resuspended in PBS for use in homing studies.

2.16 In vivo homing of labeled SG6 cells
The in vivo migration of SG6 cells labeled with CFSE was analyzed in several
tissues of control and CsA mice at day 22 post-BMT. A total of 5 × 106 CFSE-labeled
cells suspended in 0.1 ml of PBS were injected i.v. into tail vein of olive oil- or CsAtreated mice at day 21 post-BMT. Mice were killed after 24 hours and the distribution of
CFSE-labeled SG6 cells in different organs was measured. Tissues were removed from
euthanized animals and immediately embedded in Tissue-Tek OCT compound and snap
frozen in liquid nitrogen. Samples were cut into 10 µm tissue sections, mounted on glass
slides and observed under a fluorescent microscope. Each labeled SG6 cell was counted,
in 4-5 microscopic fields, over a 100x magnification. The mean values and their standard
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error were determined from two independent experiments containing a total of four
animals per experimental group.

2.17 Statistics
Statistical differences between experimental groups were determined using
Student’s t test, Fisher’s exact test (induction) and Two way ANOVA analysis of
variance. Differences p<0.05 were considered statistically different.
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Figure 2.1 Induction of murine syngeneic graft-versus-host disease

Lethal Irradiation
Syngeneic-ATBM

CsA (15mg/kg)

Clinical Symptoms

Olive Oil - Control

Day 0

Day 21

Weight loss
2-3 Weeks Post-CsA
Diarrhea

Figure 2.1 Induction of murine syngeneic graft-versus-host disease. C3H/HeN recipient
mice were lethally irradiated (900 cGy) and reconstituted with 5 x 106 T cell-depleted
bone marrow (ATBM) from syngeneic aged-matched mice. Beginning on the day of
transplantation, mice were treated daily for 21 days with either 15mg/kg CsA in the
diluent olive oil or with the diluent alone. Between 2-3 weeks post-CsA animals begin to
develop clinical symptoms (weight loss and/or diarrhea).
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Table 2.1 SGVHD Grading scale for colon and liver tissues
Adapted from Bryson et al. [79]
GRADING
+/-

COLON

LIVER

Rare crypt cell necrosis

Minimal lymphocyte infiltrate in
portal area; rare bile duct epithelial
cell degeneration

1+

Definite scattered single-cell

Sparse, but definite portal lymphocyte

necrosis in crypts

infiltrate; occasional necrotic bile duct
epithelial cells

2+

Several necrotic cells in

Diffuse infiltrate in portal area;

gland, crypt abscesses present

invasion of bile ducts by inflammatory
cells

3+

4+

Confluent destruction of

Heavy infiltrate partially obscuring

glands

bile ducts; focal bile duct destruction

Loss of mucosa with

All the above plus secondary changes

formation of granulation

in hepatocytes, bile stasis, hepatocyte

tissue and pseudomembranes

necrosis and disordered architecture
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Figure 2.2 In vivo treatment with the antioxidant MnTBAP

Lethal Irradiation
Syngeneic-ATBM

CsA (15mg/kg)

Clinical Symptoms

MnTBAP (10mg/kg) or (20mg/kg)

Day -2 Day 0

Post-CsA
MnTBAP (10mg/kg)

Day 21

Diseased
2-3 Weeks Post-CsA

Figure 2.2 In vivo treatment with the antioxidant MnTBAP. C3H/HeN recipient mice
were induced to develop SGVHD as described. Antioxidant treatment was performed
either during or post-CsA therapy. For MnTBAP treatment during CsA period, mice were
treated daily for 21 days with either 15mg/kg CsA in the diluent olive oil, the diluent
alone, MnTBAP alone or CsA and MnTBAP. For MnTBAP treatment post-CsA, control
or CsA-treated mice received MnTBAP starting at day 21 post-BMT for 2-3 weeks.
Starting on day 21 post-BMT all mice are monitored for the onset of clinical symptoms
(weight loss and/or diarrhea).

44

Figure 2.3 In vivo neutralization of TNF-α

Lethal Irradiation
Syngeneic-ATBM

CsA (15mg/kg)
Day -2

Clinical Symptoms

sTNFR-1 (100µg)
Day 3

sTNFR-1 (100µg)

Day 7

Day 0

sTNFR-1 (100µg)

Day 21

Diseased
2-3 Weeks Post-CsA

Figure 2.3 In vivo neutralization of TNF-α. C3H/HeN mice were induced to develop
SGVHD as described previously. Groups of mice received either olive oil, 15mg/kg CsA,
100 µg sTNFR-1 alone or CsA and sTNFR-1. Neutralization of TNF- α started at several
time points during the CsA treatment period. Mice were monitored for clinical symptoms
of SGVHD (weight loss and/or diarrhea) starting on day 21 post-BMT. Tissue was
collected at the end of each experiment for analysis.
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Table 2.2 Antibodies used for flow cytometry analysis
ANTIBODY

SPECIFICITY

LABEL

MANUFACURER VOLUME
ADDED

Fc block

Fc receptor

None

BD Pharmingena

1 µl

F4/80

Macrophages

APC

BioLegenda

1 µl

CD4

T cells

APC

Caltagb

1 µl

αβ

TCR

FITC

BD Pharmingena

2 µl

CD62L

Naïve

PE

BD Pharmingena

5 µl

FITC

BD Pharmingena

1 µl

PE

BD Pharmingena

5 µl

phenotype
β7 integrin

Activated
lymphocyte

CD44

Memory
phenotype

a

San Diego, CA; b Burlingame, CA
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Table 2.3 Antibodies used for immunohistochemistry (IHC) analysis
ANTIBODY

SPECIFICITY

LABEL

MANUFACURER DILUTION

Rabbit Anti-

Protein tyrosine

None

Milliporea

1:50

nitrotyrosine

nitration

Goat Anti-

IgG heavy and

Oregon

Invitrogenb

1:1000

Rabbit IgG

light chains

Green 488

Mouse Anti-

MECA-367

None

BD Pharmingenc

1:1000

Anti-Rat IgG

Rat IgG

Biotin

BD Pharmingenc

1:1000

Streptavidin

Biotin

PE

Sigmad

1:1000

CD4

L3T4

FITC

eBiosciencec

1:1000

Anti-Rat IgG

Rat IgG

FITC

eBiosciencec

1:1000

MAdCAM-1

a

Temecula, CA; b Grand Island, NY; c San Diego, CA, d St. Louis, MO
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Table 2.4 Real Time RT-PCR reaction conditions for mRNA analysis
A. REVERSE TRANSCRIPTION REACTION*
Reagenta

Volume added per sample

MgCl2 25mM

4.0 µl

Buffer 10X pH.8.8

2.0 µl

PCR Nucleotide Mix 10mM

2.0 µl

Oligo (dT) 500µg/ml

1.0 µl

RNasin 40U/µl

0.5 µl

AMV Reverse Transcriptase

0.6 µl

B. PCR REACTION (Master Mix)
Reagent

Volume added per sample

Enzyme Diluentb

1.125 µl

dNTPb 10X 2mM

1.250 µl

Bufferb 10X w/BSA 30 mM MgCl2

1.250 µl

Primerc

0.250 µl

Sybr Greend 5X

0.625 µl

dH2O

5.375 µl

Platinum Taq DNA Polymerasee 5U/µl

0.125 µl

cDNA

2.500 µl

*

After mixing all reagents, 1µg of RNA and dH2O to 20µl were added. The tubes were
then incubated for 30 minutes at 42⁰C, then for 5 minutes at 95⁰C and 5 minutes on ice.
Samples were stored in -20⁰C freezer.
a

Reagents were purchased from Promega Corporation (Madison, WI).
Reagents were purchased from Idaho technology Inc (Salt Lake City, UT).
c
Reagents were purchased from Integrated DNA technologies (Coralville, IA).
d
Reagents were purchased from Molecular probes (Eugene, OR).
e
Reagents were purchased from Invitrogen (Grand Island, NY).
b
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Table 2.5 Polymerase chain reaction (PCR) primers and conditions
PRIMERS*
GAPDHa

SEQUENCE
Forward 5’-TGCACCACCAACTGCTTA-3’
Reverse 5’-GGATGCAGGGATGATGTTC-3’

TNF-αa

Forward 5’-CATCTTCTCAAAATT CGAGTGACAA-3’
Reverse 5’-TGGGAGTAGACAAGGTACAACCC-3’

iNOSa

Forward 5’-TGACGGCAAACATGACTTCAG-3’
Reverse 5’-GCCATCGGGCATCTGGTA-3’

SOD-1a

Forward 5’-AAGGCCGTGTGCGTGCTGAA-3’
Reverse 5’-CAGGTCTCCAACATGCCTCT-3’

GPxa

Forward 5’-CCTCAAGTACGTCCGACCTG-3’
Reverse 5’-CAATGTCGTTGCGGCACACC-3’

CATa

Forward 5’-GCAGATACCTGTGAACTGTC3’
Reverse 5’-GTAGAATGTCCGCACCTGAG -3’

MAdCAM-1a

Forward 5’-GACACCAGCTTGGGCAGTGT-3’
Reverse 5’-CAGCATGCCCCGTACAGAG-3’

ICAM-1a

Forward 5’-GGGACCACGGAGCCAATT-3’
Reverse 5’-CTCGGAGACATTAGAGAACAATGC-3’

VCAM-1a

Forward 5’-CTGAATACAAAACGATCGCTCAA-3’
Reverse 5’-GCGTTTAGTGGGCTGTCTATCTG-3’

CCR5a

Forward 5’-CAAGACAATCCTGATCGTGCAA-3’
Reverse 5’-TCCTACTCCCAAGCTGCATAGAA-3’

CCL5 b

Forward 5’-TGCCCACGTCAAGGAGTATTT-3’
Reverse 5’-TCTCTGGGTTGGCACACACTT-3’

CCL20 c

Forward 5’-CTGCTGGCTCACCTCTGCA-3’
Reverse 5’-CATCGGCCATCTGTCTTGTG-3’
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Table 2.5 (Cont.) Polymerase chain reaction (PCR) primers and conditions

*

All the primers were purchased from Integrated DNA technologies (Coralville, IA).

a

95⁰C for 10 minutes, followed by 50 cycles of 30 seconds at 95⁰C, 30 seconds at
60⁰C, 30 seconds at 72⁰C and 72⁰C for 10 minutes
b
95⁰C for 10 minutes, followed by 50 cycles of 30 seconds at 95⁰C, 30 seconds at
64⁰C, 30 seconds at 72⁰C and 72⁰C for 10 minutes
c
95⁰C for 10 minutes, followed by 50 cycles of 30 seconds at 95⁰C, 30 seconds at
56⁰C, 30 seconds at 72⁰C and 72⁰C for 10 minutes
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CHAPTER THREE: ROLE OF OXIDATIVE STRESS IN SGVHD
3.1

Synopsis
Under normal physiological conditions, the production of reactive oxygen species

(ROS) as well as reactive nitrogen species (RNS) function as signaling molecules in
many processes including cell cycle and metabolism [129, 130]. When the balance
between levels of intermediate species is disrupted the harmful effects overcome the
beneficial ones interrupting redox homeostasis. For this reason, there are several
molecules that exist to counteract the damaging effects of oxidative stress and are known
as antioxidants. This group of protective molecules include enzymes like superoxide
dismutase (SOD), catalase and glutathione peroxidase (Gpx) [131]. Thus, oxidative stress
production can be defined as the imbalance between the generation of free radicals,
including their intermediates and the incapacity of antioxidant activity to reduce their
effect. Recently, the concept of oxidative stress has been extended to not only ROS, like
superoxide radicals and hydrogen peroxide but also includes RNS such as nitric oxide
(NO), peroxynitrate and S-nitrosothiols [130]. Nitric oxide reacts with superoxide (O2-) to
form peroxynitrite (ONOO-), a highly reactive species that induces nitrative and oxidative
DNA damage [103, 107]. The role of oxidative stress in the pathophysiology of diseased
states [88, 99, 126, 132] has led to the development of metalloporphyrin catalytic
antioxidants as possible therapeutic agents. Manganese (III) meso-tetrakis (4-benzoic
acid) porphyrin (MnTBAP) is a stable metalloporphyrin that can scavenge a broad
spectrum of reactive oxygen and nitrogen species [133-137]. This compound can
scavenge peroxynitrite [137], catalyze the dismutation of superoxide [136] and hydrogen
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peroxide [135], inhibit lipid peroxidation [134] as well as protect DNA from ROSmediated damage. MnTBAP has been successfully used to prevent oxidant-induced
injury responses by activated macrophages both in vitro and in vivo [135, 136]. Since it
has been implied that ROS is a mediator of CsA toxicity, and CsA treatment is a
prerequisite for SGVHD induction, studies were undertaken to investigate the role of
oxidative stress in the induction of SGVHD by treating mice with the antioxidant
MnTBAP. Tissues from C3H/HeN mice were taken at various time points and analyzed
for the presence of oxidative stress as well as proinflammatory cytokine expression and
SGVHD induction.

3.2

Determination of intracellular reactive oxygen species
Intracellular ROS production was determined by using the fluorescent probe

DCFH-DA. When the diacetate form of DCFH (DCFH-DA) is added to cells, it diffuses
across the cell membrane and is hydrolyzed by intracellular esterases to give 2’,7’dichlorofluorescin (DCFH), the oxidation of which yields fluorescent DCF [127] that can
be monitored by flow cytometry. DCFH-DA labeled spleen cells were monitored, as an
indicator of changes in ROS during SGVHD induction (days 0-21 post-BMT) (Figure
3.1, A) as well as during the post-CsA period, when clinical symptoms of disease were
evident (Figure 3.1, B). Oxidation of DCFH-DA to fluorescent DCF was significantly
increased in CsA-treated animals by day 21 post-BMT (P=0.0240; Figure 3.1, A) as well
as during active disease (P=0.0307; Figure 3.1, B) when compared to transplant control
mice, demonstrating higher levels of ROS in CsA-treated animals.
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3.3

Increased NO production in CsA-treated mice
Since our data demonstrated elevated levels of ROS, we then decided to

investigate if increases in RNS could also be detected during the development of
SGVHD. Nitric oxide was particularly intriguing because of the relationship that had
been identified between NO and gut pathology during allogeneic GVHD [105], as well as
in the pathological processes that are associated with the development of murine SGVHD
[100]. Real time RT-PCR studies were performed to determine if increases in mRNA for
iNOS could be detected in the colon, one of the target organs of SGVHD, during the
period of CsA therapy (Figure 3.2, A). Increased mRNA for iNOS was present in the
colon of CsA-treated animals as early as day 14 (P=0.0262) and at day 21 post-BMT
(P=0.0011). As previously published by our group [100], iNOS mRNA levels remain
significantly elevated during active disease in colonic tissue of CsA-treated mice
compared to BMT control (P=0.0146). Preliminary studies confirmed the PCR findings
in that increases in circulating NO were observed in the plasma/serum of SGVHD mice
relative to normal or transplant control animals (Figure 3.2, B). As another measure of
oxidative stress in the tissues of CsA-treated/SGVHD animals we monitored protein
tyrosine nitration since it is an important marker of oxidative stress induced by
peroxynitrite and other nitric-oxide derived oxidants [99, 130]. Our results show
increased nitrotyrosine in colonic tissue of CsA-treated mice compared to control mice by
day 21 post-BMT (Figure 3.3, A) as well as during disease period (Figure 3.3, B),
demonstrating increased oxidation mediated by peroxynitrite. Taken together, these
results demonstrate that CsA-treated mice produced significantly elevated amounts of
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RNS compared to control BMT mice and confirm that increased oxidative stress is
generated in mice undergoing CsA therapy.

3.4

Reduction of oxidative stress during CsA therapy alters the

development of SGVHD
To determine the role of conditioning-induced oxidative stress on the
development of SGVHD, the antioxidant MnTBAP, a stable metalloporphyrin that can
scavenge a broad spectrum of reactive oxygen and nitrogen species [133-137], was given
to control BMT and CsA mice during the CsA therapy period. C3H/HeN mice were
lethally irradiated, reconstituted with syngeneic BM and treated with CsA for 21 days as
described. Beginning two days prior to BMT, the mice were treated with MnTBAP, 10
mg/kg twice a day until day 21 post-BMT. Twice a day dosing regimen was performed
based on the MnTBAP elimination half-time of 9.5 hours, as indicated by toxicology data
[126]. Treatment of CsA mice with MnTBAP was able to significantly delay the
induction of SGVHD in these animals compared to the ones that received CsA alone
(Figures 3.4, A, B and C). Antioxidant therapy during CsA treatment delayed weight
loss observed in the CsA-treated mice (Figure 3.4, A) as well as delayed development of
clinical symptoms of SGVHD (P= 0.0023; Figure 3.4, B) and total disease induction (P=
0.0240; Figure 3.4, C).
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3.5

Decreased iNOS and TNF-α mRNA levels after MnTBAP therapy

during CsA treatment
Since the data showed increased levels of iNOS mRNA and RNS in CsA-treated
animals compared to control BMT mice during CsA therapy (Figure 3.2), studies were
undertaken to determine if treatment with the antioxidant MnTBAP was capable of
reducing iNOS levels in CsA-treated animals during this time frame after BMT. Real
time RT-PCR studies revealed a decrease in iNOS mRNA levels in CsA-treated mice that
were treated with MnTBAP (10 mg/kg) at day 21 post-BMT (Figure 3.5, A), suggesting
that MnTBAP therapy was able to reduce NO production by inhibiting the iNOS enzyme.
Similarly, Garcia-Ruiz et al. recently demonstrated that iNOS activity was reduced
following MnTBAP therapy in the murine model of non-alcoholic fatty liver disease
(NAFLD) [138].

Additionally, TNF-α mRNA levels were analyzed since increased

mRNA levels of this proinflammatory mediator in colonic tissue of CsA-treated mice
were observed by day 21 post-BMT (refer to Chapter 4 of dissertation; Figure 4.3).
MnTBAP therapy was able to decrease TNF-α mRNA levels in the colon of CsA-treated
mice when compared to CsA mice that did not receive the antioxidant therapy (Figure
3.5, B). While there was a clearly identified trend, the reduction in iNOS and TNF-α
mRNA levels were not statistically significant (p≥0.05). The mRNA levels of the
proinflammatroy cytokines IL-12 and IFN-γ, which are known to mediate SGVHD [80,
83] were also analyzed by real time RT-PCR at day 21 post-BMT and as shown in
Figure 3.6, MnTBAP therapy did not reduce their levels in the colonic tissue of CsAtreated mice.
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3.6

Effect of MnTBAP treatment during CsA therapy on generation

of oxidative stress
Our results demonstrated that treatment of CsA mice with an antioxidant reduced
the severity of SGVHD when compared to mice receiving CsA alone. However, the
mechanism(s) by which the SOD mimetic exerted its beneficial actions remained
unknown. Given that the levels of nitrotyrosine in colonic tissue of CsA-treated mice
were elevated when compared to transplanted controls (Figure 3.3), we analyzed the
levels of this oxidative stress marker in control, CsA and CsA-MnTBAP treated mice at
day 21 post BMT (Figures 3.7). Immunohistochemistry analysis revealed less
nitrotyrosine staining in the colons of CsA mice that also received MnTBAP compared to
mice treated with CsA alone (Figure 3.7, A). In addition, the quantitative measure of
nitrotyrosine staining in colonic tissue revealed that MnTBAP treatment was capable of
reducing oxidative stress in a significant manner when compared to mice that were only
treated with CsA (Figure 3.7, B). These studies demonstrated that treatment with the
SOD mimetic reduced production of peroxynitrite in the colon of CsA-treated mice,
reducing a potent RNS mediator that has been shown to be unregulated during intestinal
inflammation of IBD [99].

3.7

Reduction of oxidative stress post-CsA therapy alters the

development of SGVHD
Since our results demonstrated that antioxidant therapy during the 21 days of CsA
induction therapy was able to delay disease induction, we analyzed the role of oxidative
stress post-CsA therapy in the development of SGVHD. For these experiments, treatment
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with the antioxidant MnTBAP was given to BMT control and CsA mice after cessation of
CsA therapy. C3H/HeN mice were lethally irradiated and reconstituted with syngeneic
BM and treated with CsA for 21 days as described. Beginning on day 21 post-BMT, the
mice were treated with MnTBAP 10 mg/kg twice a day for 2-3 weeks until CsA-treated
mice were positive for SGVHD (≥ 80%). Treatment of control and CsA-treated mice with
MnTBAP in the post-CsA period delayed the development of clinical symptoms of
SGVHD (Figures 3.8, A, B and C). Antioxidant therapy post-CsA treatment reduced
weight loss observed in the CsA-treated mice (Figure 3.8, A). Clinical symptoms of
SGVHD, including weight loss, diarrhea and/or death were decreased in CsA-treated
mice that also received MnTBAP compared to mice that did not receive the antioxidant
therapy (P= 0.0050; Figure 3.8, B). In addition, total disease induction was significantly
reduced by antioxidant therapy post-CsA period (P= 0.0003; Figure 3.8, C). Since iNOS
mRNA levels were shown to be up-regulated during SGVHD (Figure 3.2), real time RTPCR analysis was performed to evaluate the effect that MnTBAP therapy had on the
generation of iNOS mRNA at this stage of disease. Results showed decreased iNOS
mRNA levels after antioxidant treatment in the colon of CsA-treated mice if compared to
mice that received CsA alone (Figure 3.9). In addition, MnTBAP treatment in the postCsA period was also capable of reducing nitrotyrosine staining in CsA-treated mice as
shown in Figure 3.10. These results were not surprising as our group had previously
shown that inhibition of iNOS post-CsA therapy decreased SGVHD induction [100].
Interestingly, histological analysis of colonic tissue revealed that MnTBAP treatment
post-CsA therapy did not ameliorate disease pathology observed in CsA-treated mice
(Figure 3.11) and was confirmed by immunohistochemistry analysis of CD4+ T cells in
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which migration of these effector cells into the colon of CsA-treated mice was not
decreased by antioxidant therapy (Figure 3.12).

3.8

Summary
The results presented in this chapter confirm the hypothesis that SGVHD

induction results in increased oxidative stress in CsA-treated mice compared to BMT
controls. Treatment with a commercially available SOD mimetic, MnTBAP, during the
21 days of CsA therapy as well as post-CsA period resulted in delayed disease induction
and clinical symptoms of SGVHD. However, the reduction of proinflammatory mediators
and oxidative stress was not enough to completely ameliorate disease induction.
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Figure 3.1 Elevated ROS in mice treated with CsA compared to control BMT
p=0.0240

Mean Flourescence Intensity

A

*

n=15

200

n=12
100

0

Control

CsA

B
100

p=0.0307

75

+

% DCFH-DA F4/80

+

*

n=7

n=7
50

25

0
Control

CsA

Figure 3.1 Elevated ROS in mice treated with CsA compared to control BMT. Spleen
cells from CsA-treated mice produce increased levels of DCFH-DA. Spleens were
removed from control and CsA-treated mice at day 21 post-BMT (A) or during active
disease (B). Splenocytes were isolated and treated with DCFH-DA, as described and
analyzed by flow cytometry. Data presented is pooled from four individual experiments,
n represents the number of animals per group.
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Figure 3.2 Increased reactive nitrogen species in CsA-treated mice
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Figure 3.2 Increased reactive nitrogen species in CsA-treated mice. (A) Increased levels
of iNOS mRNA in CsA-treated mice. Animals were induced to develop SGVHD as
described. Tissue isolated from the colon at several time points was analyzed by real time
RT-PCR. Data is representative of two experiments with n representing the number of
mice. (B) Circulating NO is increased in CsA-treated animals. Normal, control, and CsAtreated BMT recipient mice were bled at several time points during CsA therapy. Serum
was collected, and nitrate was reduced to nitrite by nitrate reduction and analyzed for the
presence of NO2⎯. Data is representative of one experiment.
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Figure 3.3 Increased levels of nitrotyrosine in the colons of CsA-treated mice

A

B

Figure 3.3 Increased levels of nitrotyrosine in the colons of CsA-treated mice compared
to transplant controls. Colon tissue was isolated at day 21 post-BMT (A) and during
SGVHD (B) and frozen sections analyzed for the presence of nitrotyrosine, a marker of
RNS by IHC analysis. Slides were visualized under 100x magnification. The data
presented are representative of samples from four mice from two individual experiments.
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Figure 3.4 MnTBAP treatment delayed the development of SGVHD
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Figure 3.4 (Cont.) MnTBAP treatment delayed the development of SGVHD
C. Decreased SGVHD total induction after MnTBAP therapy
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Figure 3.4 MnTBAP treatment delayed the development of SGVHD. Disease was
induced in C3H/HeN mice, as described. Groups of control or CsA-treated mice were
given 10 mg/kg of MnTBAP twice a day starting 2 days prior to BMT and every day for
21 days. The animals were then monitored for SGVHD induction (weight loss, diarrhea
and/or mortality). (A) Animals were weighed individually 3x per week starting on day 21
post-BMT. Data presented represent pooled data from 2 experiments, plotted as average
± SEM of percent weight change for each treatment group (n = 16); (B) Animals were
followed for induction and plotted as average ± SEM for the time to induction after BMT.
Data presented represent pooled data from 4 experiments (n = 16); (C) Analysis for
induction measured 49 days post-BMT, with the number of animals with SGVHD/total
number of animals within each group presented above each bar. Data presented are
pooled from four experiments.
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Figure 3.5 MnTBAP therapy resulted in decreased colonic iNOS and TNF-α
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Figure 3.5 MnTBAP therapy resulted in decreased colonic (A) iNOS and (B) TNF-α.
C3H/HeN mice were induced for SGVHD and treated with MnTBAP as described. On
the day after the last MnTBAP treatment, the colon was removed from control, CsAtreated, MnTBAP-control, and MnTBAP-CsA-treated animals. Messenger RNA was
isolated and analyzed by real time RT-PCR. Data presented are pooled from three
individual experiments, n represents the number of mice per group.
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Figure 3.6 MnTBAP therapy did not reduce IL-12 or IFN-γ mRNA levels
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Figure 3.6 MnTBAP therapy did not reduce IL-12 or IFN-γ mRNA levels. SGVHD was
induced as described and mRNA was isolated from the colons of control, CsA, MnTBAP
and CsA+MnTBAP treated animals at day 21 post-BMT. Real time RT-PCR was
performed for IL-12 (A) and IFN-γ (B). Data presented are the mean ± SEM, from
pooled samples of four independant experiments, n represents the number of mice per
group.
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Figure 3.7 Reduced nitrotyrosine staining after antioxidant therapy
A. Immunohistochemistry staining of nitrotyrosine at day 21 post-BMT

B. Quantitative measure of nitrotyrosine staining on day 21 colonic tissue
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Figure 3.7 Reduced nitrotyrosine staining after antioxidant therapy. Colons of C3H/HeN
mice were removed at day 21 post-BMT and frozen sections were analyzed by
immunohistochemistry techniques for the presence of nitrotyrosine (A). Slides were
visualized under 100x magnification and staining per field was quantified (B). The data
presented are representative of samples from four mice from two individual experiments.
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Figure 3.8 Delayed SGVHD after MnTBAP treatment post-CsA
A. Antioxidant therapy reduced weight loss in CsA mice
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Figure 3.8 (Cont.) Delayed SGVHD after MnTBAP treatment post-CsA
C. Decreased SGVHD total induction after MnTBAP therapy
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Figure 3.8 Delayed SGVHD after MnTBAP treatment post-CsA. Disease was induced
in C3H/HeN mice, as described and groups of control or CsA-treated mice were given 10
mg/kg of MnTBAP twice a day beginning on day 21 post-BMT and every day up to 2-3
weeks, when the majority (> 80%) of the CsA animals had developed SGVHD. Animals
were monitored for clinical symptoms of SGVHD. (A) Animals were weighed
individually 3x per week starting on day 21 post-BMT and plotted as average ± SEM of
percent weight change for each treatment group. (B) Animals were followed for
induction and plotted as average ± SEM for the time to induction after BMT. (C)
Analysis for induction measured 43 days post-BMT, with the number of animals with
SGVHD/total number of animals within each group presented above each bar. Data
presented are pooled from two experiments. Control n = 9, CsA n = 15, MnTBAP n = 12
and CsA+MnTBAP n = 16.

68

Figure 3.9 MnTBAP therapy reduced mRNA levels of iNOS
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Figure 3.9 MnTBAP therapy reduced mRNA levels of iNOS. C3H/HeN mice were
induced for SGVHD, as described and treated with MnTBAP post-CsA therapy. On the
day after the last MnTBAP treatment, the colon was removed from each experimental
group and mRNA was isolated from the colonic tissue. Real time RT-PCR was
performed for iNOS. Data presented are pooled from two independent experiments, n
represents the number of animals analyzed.
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Figure 3.10 Decreased RNS in colon of CsA-treated mice after MnTBAP therapy
A. Immunohistochemistry staining of nitrotyrosine at day 21 post-BMT

B. Quantitative measure of nitrotyrosine on SGVHD mice
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Figure 3.10 Decreased RNS in colon of CsA-treated mice after MnTBAP therapy.
Immunohistochemistry analysis of colonic tissue during diseased stage revealed
increased nitrotyrosine staining in colons of CsA-treated mice compared to control BMT
and reduced staining in CsA after antioxidant therapy (A). Quantification of nitrotyrosine
staining (B). Data is pooled from 2 experiments and represents n=4 mice per group.
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Figure 3.11 Colon pathology was not altered by MnTBAP treatment
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Figure 3.11 Colon pathology was not altered by MnTBAP treatment. Histological
examination of SGVHD colons shows no difference after antioxidant therapy. Colon
tissue was isolated during clinical symptoms of SGVHD, typically 3–4 weeks post-CsA
treatment. The tissues were stained using H&E staining procedure and pathology grading
was performed as described in Materials and Methods. Data represents mean grade ±
SEM, n represents the number of mice per experimental group pooled from two
independent experiments.
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Figure 3.12 Migration of T cells into the colon was not reduced by MnTBAP

Figure 3.12 Migration of T cells into the colon was not reduced by MnTBAP.
Immunohistochemistry staining of CD4+ T cells in colonic tissue of SGVHD mice. Colon
tissue from control BMT, CsA and CsA-MnTBAP treated animals was collected at day
43 post-BMT and frozen sections were stained for the presence of CD4+ T cells. Colons
from CsA animals show increased levels of CD4 staining compared to control BMT but
MnTBAP treatment had no effect on inhibiting T cell migration into the colon of CsAtreated mice. The data presented are representative of n=4 from two individual
experiments.
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CHAPTER FOUR: ROLE OF T CELL HOMING IN SGVHD

4.1

Synopsis
Histological studies have demonstrated severe colonic tissue damage in SGVHD

mice caused by massive infiltration of inflammatory cells, particularly CD4+ T cells, into
the colon of CsA-treated mice [55, 78, 80, 83, 100, 139]. Bryson et al. demonstrated a
role for CD4+ T cells in the induction of colitis observed in murine SGVHD. Increased
CD4+ but not CD8+ T cells were observed in the colons of diseased animals.
Additionally, in vivo depletion of CD4+ T cells during CsA therapy inhibited significantly
the induction of SGVHD [78] and SGVHD can be adoptively transferred with CD4+ T
cells from diseased animals into secondary recipients [58]. Previously published studies
have demonstrated that an increase in colonic CD4+ T cells was observed in CsA-treated
mice by day 21 post-BMT, suggesting that enhanced T cell migration into the colon
occurred during the CsA treatment period [78]. Studies were then undertaken to follow
the migration of T cells at the early stages after BMT and investigate the mechanism that
could result in the increased intestinal migration of CD4 effector T cells during the
induction of SGVHD. Tissues from C3H/HeN mice were taken at various time points
during CsA treatment and analyzed for the presence of CD4+ T cells, CAM, chemokines
and proinflammatory cytokines associated with T cell homing into the gut. In vivo studies
were performed using a CFSE-labeled SGVHD CD4+ T cell line to investigate where
these T cells preferentially migrate. These investigations allowed us to gain a better
understanding of the functional mechanisms that take place, during the 21 days of
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induction/immunosuppression therapy, that result in the increased homing of effector T
cells into colons of CsA-treated mice.

4.2

Enhanced CD4+αβTCR+ T cells in colons of CsA-treated mice

compared to control BMT
Previous studies have shown significant increases in colonic CD4+ T cells isolated
from SGVHD mice at 2–4 weeks post-CsA (5–7 weeks post-BMT) relative to transplant
control animals [78]. In addition, a 2-fold increase in CD4+ T cells was also observed in
the IEL isolated from CsA versus BMT control mice 21 days after transplant, at the end
of CsA therapy [78]. These studies suggested that increased numbers of CD4+ T cells
migrated into the colon of CsA-treated mice during CsA therapy. Studies were therefore
initiated to follow the migration of T cells into the colon during the CsA treatment period
(days 0-21 post-BMT). For these experiments, colons were isolated from control and
CsA-treated mice at several time points during the 21 days of CsA therapy and the IEL
and LPLs were isolated and analyzed by flow cytometry for various T cell markers. As
shown in Figure 4.1, A an increased percentage of CD4+αβTCR+ T cells was found in
the colons of CsA-treated mice as early as day 14 post-BMT (P=0.0288) and they
maintained this increase through day 21 post-BMT (P=0.0001). Lamina propia
lymphocytes isolated from CsA versus control also showed an increased percent of
CD4+αβTCR+ T cells as well (Figure 4.1, B). Intraepithelial lymphocytes and LPL were
also analyzed during active disease and confirmed previous results in which SGVHD
mice had increased infiltration of CD4+ T cells into their large intestine compared to
control BMT animals (Fig 4.1, A, B). Immunohistochemistry analysis was performed to
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confirm the flow cytometry analysis of isolated cells. In situ analysis demonstrated
increased CD4+ T cell staining in the colonic tissue of CsA-treated mice compared to
control BMT at days 14 and 21 post-BMT (Figure 4.2).

4.3

Increased

proinflammatory

mediators

and

cell

adhesion

molecules (CAM) during SGVHD
Total body irradiation (TBI) can affect the severity of many diseases by
amplifying the dysregulation of inflammatory cytokines. Irradiation along with allogeneic
immune cells can damage the gastrointestinal (GI) tract, which allows for increased
translocation of lipopolysaccharide (LPS) into the systemic circulation leading to
increased levels of TNF-α [140]. Radiation has also been shown to stimulate macrophage
production of proinflammatory cytokines in a dose dependant manner [141]. Using the
murine model of SGVHD, Bryson et al. observed a significant increase in the migration
of CD4+ T cells into colons of CsA-treated animals during active disease [78]. Several in
vivo and in vitro studies have demonstrated that endothelial cells (EC) respond to stimuli
such as irradiation, LPS and TNF-α by either becoming activated or undergoing apoptosis
[140, 142]. Additionally, early interactions between allogeneic lymphocytes and vascular
endothelial cells correlate with up-regulated mRNA levels of adhesion molecules, as well
as TNF-α, which can result in lymphocyte adherence and EC injury [143]. TNF-α is an
inflammatory cytokine capable of inducing cell adhesion molecules such as VCAM-1,
ICAM-1[119] and MAdCAM-1 [120]. Studies were therefore designed to examine the
levels of adhesion molecules, TNF-α and proinflammatory chemokines in colonic tissue
of CsA and control BMT mice. Real time RT-PCR assays were performed to determine if
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increases in mRNA for TNF-α and CAM could be detected in the colon of CsA-treated
animals. Results from a time course study revealed significantly increased mRNA levels
for TNF-α at days 14 and 21 post-BMT in colonic tissue of CsA mice compared to BMT
control (P=0.0009 at day 14 post-BMT; P=0.0387 at day 21 post-BMT; Figure 4.3).
Concomitant with this increase in proinflammatory cytokine production, colons of
CsA mice had increased mRNA levels of CAM as early as day 14 post-BMT compared
to control mice (Figure 4.4). MAdCAM-1 mRNA analyzed by real time RT-PCR
revealed significantly increased levels at days 14 and 21 post-BMT in CsA-treated mice
compared to BMT control mice (P=0.0358 at day 14; P=0.0006 at day 21 post-BMT
Figure 4.4, A). Similar results were observed for VCAM-1 (P=0.0179 at day 14;
P=0.0478 at day 21 post-BMT Figure 4.4, B) and ICAM-1 (P=0.0347 at day 14;
P=0.0070 at day 21 post-BMT Figure 4.4, C). Immunohistochemistry staining of
MAdCAM-1 expression confirmed the elevated levels of CAM in colonic tissue of CsAtreated mice. Increased levels of MAdCAM-1 were observed as early as day 14 postBMT in colons of CsA-treated mice compared to control BMT and this expression was
sustained during the time course study up to the period of active disease for SGVHD
(Figure 4.5).
Chemokines play an important role in lymphocyte trafficking to specific sites,
regulating immune responses and homeostasis. Radiation therapy is capable of disrupting
the epithelial integrity leading to an inflammatory response and hence increased
expression of proinflammatory cytokines and chemokines [140, 142, 144]. The
constitutive presence of these regulators allows for the trafficking of lymphocytes into the
gastrointestinal mucosal compartment disrupting the physiological balance and
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contributing to pathogenesis like inflammatory bowel diseases (IBD) [111, 112]. Since
many studies have confirmed increases in proinflammatory chemokines (i.e. CCL20,
CCR6, CCR5, CCL5) during gut inflammation [111-113], experiments were performed
to investigate if chemokines associated with mucosal homing were up-regulated during
CsA treatment. Figure 4.6 shows significant increases in mRNA levels of CCL20
(Figure 4.6, A; p=0.0089), CCR5, its ligand CCL5 (Figure 4.6, B; p=0.0150 and Figure
4.6, C; p=0.0406) and its ligand CCL3 (data not shown), in the gut of CsA-treated mice
compared to controls at day 21 post-BMT. This significant increase in mediators and
ligands were present in CsA-treated versus control BMT mice, suggesting a role for these
molecules in the enhanced migration of CD4+ T cells into the colon of CsA-treated
animals.

4.4

Increased homing of labeled SGVHD T cells into the colons of

CsA-treated mice
An increase in the migration of CD4+ T cells was observed into the colons of
CsA-treated mice compared to control BMT as early as day 14 post-BMT and this
increase correlated with an increase in CAM and chemokines associated with mucosal
homing. Studies were undertaken to determine if increases in these molecules was
indeed functional. Since increased homing of CD4+ T cells were observed in the colonic
tissue of CsA-treated mice, along with increased β7 integrin expression (preliminary
data), we hypothesized that the most likely CAM involved in the trafficking of these
lymphocytes to the gut is MAdCAM-1, which has been previously implied to be upregulated in gut inflammation [109, 116]. For these experiments, a long term microbial
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Ag-specific CD4+ T cell line isolated from SGVHD animals was used to study the
homing of lymphocytes into several organs of control and CsA-treated mice.
Phenotypically the CD4+ T cell line (SG6) was β7 integrin+ (Figure 4.7) and had an
activated phenotype (CD62L⎯, CD44hi; data not shown). Stimulation of the SG6 cells
with APC pulsed with bacterial Ag resulted in a significant proliferative response
compared to APC alone (Figure 4.8). Similar responses have been observed in primary
CD4+ T cells isolated from SGVHD mice compared to those from BMT control animals
[58]. To determine if these CD4+β7integrin+ SGVHD T cells would migrate at a higher
frequency to the colon of CsA-treated mice versus that of control animals, SG6 cells
labeled with CFSE were injected i.v. into the tail of control and CsA-treated mice at day
21 post-BMT. At this time point post-BMT increased expression of CAM and
chemokines is present in CsA-treated mice (Figures 4.4-4.6). Tissues were isolated 24 h
after SG6 injection and analyzed by fluorescent microscopy. Increased levels of SG6labeled cells migrated into the colons of CsA-treated mice compared to control BMT
(Figure 4.9, A). Similar increases in migration were also observed in the liver as well
(data not shown). When the number of labeled SG6 were enumerated, a significant
increase in the migration of these labeled CD4+ T cells into the colonic tissue of mice
treated with CsA (P=0.0038) was observed compared to control BMT animals (Figure
4.9, B), supporting the observation that increases in CAM were functional for the
migration of CD4+ T cells observed in the colons of CsA-treated mice.
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4.5

CD4+ T cell migration into the liver
The liver, along with the colon, represent the main target organs affected by the

development of murine SGVHD. Histological evaluation of tissue samples from SGVHD
mice have demonstrated increased lymphocytic infiltration of the colon and liver of CsAtreated compared to control BMT animals. Studies from this laboratory have
demonstrated that there was a 100% correlation between liver and colon inflammation. In
addition, the adoptive transfer of CD4+ T cells from SGVHD mice into secondary
recipients, not only resulted in colon pathology, but liver inflammation as well that was
identical to de novo SGVHD [58]. The chronic liver inflammation that occurs during the
development of murine SGVHD is very similar to that observed during the early stages of
primary sclerosing cholangitis (PSC). Primary sclerosing cholangitis is a chronic
inflammatory process of intra- and extra-hepatic bile ducts [145-147] and has been
frequently associated with inflammatory bowel disease (IBD) [148, 149]. In addition,
expression of MAdCAM-1 and CCL25, which are typically restricted to the endothelium
of the gut mucosa have been shown to be upregulated on the portal endothelium of the
liver, allowing the recruitment of α4β7+, CCR9+, CD4+ memory T cells to the liver from
the gut [150]. Given the similarities between IBD, SGVHD and chronic liver
inflammation, preliminary studies were initiated to monitor CD4+ T cell migration into
the livers of control BMT and CsA-treated animals. Immunohistochemistry analysis of
liver samples at several time points after BMT revealed that while these CD4+ T cells are
observed as early as day 14-post BMT in the colon of CsA mice (Figure 4.2), they are
not present in the liver until active disease (Figure 4.10). Furthermore, mRNA analysis
of liver samples for MAdCAM-1 at day 14 post-BMT revealed no difference between
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CsA and control mice, but a slight increase at day 21 pos-BMT (Figure 4.11) and
significant difference during active disease (data not shown). In addition, as stated above,
similar to murine colitis models, our results have demonstrated enhanced responsiveness
of SGVHD CD4+ T cells against antigens isolated from cecal bacterial preparations.
These studies suggest that there is an ordered migration of T cells reactive against
bacterial antigens from the gut into the liver during the development of SGVHD.

4.6

Summary
The data in this chapter represents the first demonstration that the CD4+ T cells

responsible for the pathogenesis observed in murine SGVHD are increased as early as
day 14 post-BMT in the colons of CsA-treated mice compared to BMT controls,
suggesting that during the 21 days of immunosuppressive therapy these CD4+ T cells are
either migrating or expanding into the intestines of these animals in a CsA-resistant
manner. Concurrent with these findings, elevated expression of CAM, chemokines and
proinfllammatory cytokines, shown to be involved in gut inflammation, were also
elevated in the colon of CsA-treated mice. Finally, in vivo homing studies using CD4+ T
cells from SGVHD animals confirmed increased migration of these effector cells into the
colon of CsA-treated mice, suggesting a functional role for the increased CAM
expression observed in CsA-treated animals.
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Figure 4.1 Enhanced numbers of CD4+ IEL and LPL isolated from CsA-treated animals
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Figure 4.1 Enhanced numbers of CD4+ IEL and LPL isolated from CsA-treated animals.
C3H/HeN mice were lethally irradiated, reconstituted with syngeneic BM and treated for
21 days with 15 mg/kg of CsA i.p. At times after BMT, colons from mice were isolated
and pooled within each experimental group. After isolation, (A) IEL and (B) LPL cells
were stained with mAb for CD4 and αβTCR and analyzed by flow cytometry. Data is
presented as the mean ± SEM, with n representing the number of experiments performed.
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Figure 4.2 Elevated CD4 expression in colonic tissue of CsA-treated mice compared to
control BMT

Figure 4.2 Elevated CD4 expression in colonic tissue of CsA-treated mice compared to
control BMT. Immunohistochemistry staining revealed increased CD4+ T cells in colonic
tissue of CsA-treated mice. Colon tissue from control BMT and CsA animals was
collected at several time points (Days 14, 21 and 37) and frozen sections were stained for
the presence of CD4+ T cells. Colons from CsA animals (top panel) show increased
levels of CD4 staining compared to control BMT (lower panel). The data presented are
representative of n=6 from two individual experiments.
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Figure 4.3 Increased production of TNF-α in colonic tissue of CsA-treated mice
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Figure 4.3 Increased production of TNF-α in colonic tissue of CsA-treated mice.
C3H/HeN mice were induced for SGVHD as described. Tissue isolated from the distal
colon was taken at the indicated time points during CsA treatment and analyzed by real
time RT-PCR for the presence of mRNA for TNF-α. Data presented are the mean ± SEM,
with n representing the number of animals analyzed in each group pooled from two
independent experiments.
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Figure 4.4 Elevated levels of CAM mRNA in the colon of CsA-treated mice compared
to control BMT
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Figure 4.4 (Cont.). Elevated levels of CAM mRNA in the colon of CsA-treated mice
compared to control BMT
p=0.0070
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Figure 4.4 Elevated levels of CAM mRNA in the colon of CsA-treated mice compared
to control BMT. RNA was isolated from the colons of control BMT and CsA-treated
animals at the indicated time points. Real time RT-PCR was performed for (A)
MAdCAM-1, (B) VCAM-1 and (C) ICAM-1. Data represents pooled results of two
experiments and is shown as the mean ± SEM, with n representing the number of animals
analyzed in each group.
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Figure 4.5 Increased presence of MAdCAM-1 in colonic tissue of CsA-treated mice
compared to control BMT

Figure 4.5 Increased presence of MAdCAM-1 in colonic tissue of CsA-treated mice.
Colon tissue was isolated at days 7, 14, 21 and 37 after BMT, snap frozen and sections
from control BMT and CsA-treated mice were stained by immunohistochemistry
techniques for the presence of MAdCAM-1 (100x). The data presented are representative
of n=9 from three independent experiments.
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Figure 4.6 SGVHD induction results in increased production of proinflammatory
chemokines in the colon
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Figure 4.6 (Cont.) SGVHD induction results in increased production of proinflammatory
chemokines in the colon
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CsA

SGVHD induction results in increased production of proinflammatory

chemokines in the colon. Messenger RNA was isolated from the colons of control BMT
and CsA animals at day 21 post-BMT. Real time RT-PCR was performed for CCL20 (A),
CCR5 (B) and CCL5 (C). Data presented are the mean ± SEM, from pooled samples
from 2 experiments, with n=6.
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Figure 4.7 SGVHD T cell line express a CD4+β7integrin+ phenotype

Figure 4.7 SGVHD T cell line express a CD4+β7integrin+ phenotype. SGVHD T cell
line or SG6 was harvested over Ficoll and analyzed by 2-color flow cytometry for CD4
and β7integrin. Markers were set using unstained cells. Data are representative of three
independent experiments.
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Figure 4.8 SGVHD CD4+ T cell line proliferates against bacterial-Ag pulsed DC
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Figure 4.8 SGVHD CD4+ T cell line proliferates against bacterial-Ag pulsed DC. SG6
cells were harvested 8-10 days after initiation of culture and 1-2 x 105 cells were cultured
in 96-well flat-bottomed microtiter plates with 1 x 104 antigen-pulsed DC. Proliferation
was measured by the addition of [3H]-thymidine during the last 18 h of a 96 h culture.
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Figure 4.9 Increased homing of CD4+ T cells into the gut of CsA-treated mice
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Figure 4.9 Increased homing of CD4+ T cells into the colon of CsA-treated animals.
SG6 cells were labeled with CFSE and injected (i.v.) into the tail of control or CsAtreated animals at day 21 post-BMT. After 24 hr, their distribution into the colon was
visualized under a fluorescent microscope (A). Labeled SG6 cells were counted, within a
microscope field, over a 100x magnification (B). The mean values and their standard
error were determined from two independent experiments containing a total of four
animals per experimental group.
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Figure 4.10 Elevated CD4+ T cell expression in liver tissue of SGVHD mice

Figure 4.10 Elevated CD4+ T cell expression in liver tissue of SGVHD mice.
Immunohistochemistry staining revealed increased CD4+ T cells in colonic tissue of
SGVHD mice (day 37). Colon tissue from control BMT and CsA animals was collected
at several time points (Days 14, 21 and 37) and frozen sections were stained for the
presence of CD4+ T cells. Colons from CsA-treated animals (top panel) showed increased
levels of CD4 staining at day 37 post-BMT compared to control BMT (lower panel). The
data presented are representative of n=4 at days 14, 21 and n=6 at day 37 from two
individual experiments.
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Figure 4.11 MAdCAM-1 mRNA expression post-BMT in liver tissue
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MAdCAM-1 mRNA expression post-BMT in liver tissue. BMT was

performed as described. At times after BMT, control and CsA-treated animals were
killed, livers were removed and RNA prepared. Expression of MAdCAM-1 was
determined at day 14 (A) and day 21 (B) post-BMT by real time RT-PCR and normalized
to GAPDH. Data presented are the mean ± SEM from 1 experiment, with n=8.
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CHAPTER FIVE: DISCUSSION

5.1

Synopsis
Syngeneic GVHD can be induced in mice by reconstituting lethally irradiated

animals with syngeneic BM cells followed by a 21 day treatment with the
immunosuppressive agent CsA [55]. Clinical symptoms of the disease, which include
weight loss and diarrhea, appear 2 to 3 weeks after cessation of CsA therapy and
SGVHD-associated inflammation occurs primarily in the colon and liver [55]. Both
radiation and CsA are preconditioning requirements for the development of SGVHD [57,
85] and participate in the induction of oxidative stress [65, 86-88]. SGVHD development
is a multi step process resulting from the cooperative interaction of various effector cell
populations including NK cells [80], T cells [78, 97] and macrophages [83], along with
TH1 cytokines that result as a consequence of the preconditioning regimens of this disease
[80, 83]. A proposed mechanism of action of these proinflammatory mediators in
SGVHD is via their stimulation of oxidative stress. The role of oxidative stress,
specifically NO during active disease has been previously studied. Inhibition of iNOS
resulted in decreased development of SGVHD [100]. These findings, along with the
implication of oxidative stress production by the conditioning regimens, led us to
hypothesize that CsA-treated mice produce elevated levels of ROS/RNS compared to
control BMT and to investigate the role of oxidative stress in the induction of SGVHD.
Since previous studies have demonstrated a role for CD4+ T effector cells in the induction
of murine SGVHD [58, 78], studies were undertaken to follow the migration of T cells at
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the early stages after BMT and investigate the mechanism that could result in the
increased migration of CD4 effector cells during the induction protocol of SGVHD.

5.2

Role of oxidative stress in SGVHD
In Chapter Three of this dissertation we examined the role of oxidative stress in

SGVHD. This inducible disease was first described by Glazier et al. as a GVHD-like
syndrome that developed in rats following syngeneic BMT and CsA treatment [16]. Both
irradiation and CsA treatment are required for disease induction [57, 85] and participate
in the production of oxidative stress [86-90]. We became interested in studying oxidative
stress in the murine model of SGVHD since previous work had demonstrated a
significant role for oxidative stress mediators during active disease [100]. Flanagan et al.
determined the contribution of NO to the development of SGVHD by demonstrating that
in vivo inhibition of iNOS with the inhibitor aminoguanidine (AG), starting on day 21
post-BMT for up to 2 weeks (post-CsA therapy), significantly reduced the development
of disease. In their studies, iNOS inhibition resulted in the abrogation of clinical
symptoms, tissue pathology and cytokine (IL-12 and IFN-γ) production associated with
the development of SGVHD [100]. In accordance, Garside et al. [105] showed that
inhibition of iNOS with L-NG-monomethyl arginine (L-NMMA), in their experimental
model of mice GVHD, resulted in decreased intestinal pathology. In addition to these
studies looking at the effect of post-CsA iNOS inhibition, studies in allogeneic GVHD
have shown that inhibition of NO production at early stages following BMT can lead to
mortality [98, 106], suggesting that NO levels could affect alloengraftment [98] or have a
protective effect during this period [106]. For this reason we decided to treat mice with
the antioxidant MnTBAP, since it can scavenge a broad spectrum of reactive oxygen as
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well as nitrogen species [126, 135, 136, 151]. Experiments were designed to investigate
the role of oxidative stress during the induction of SGVHD by treating mice with
MnTBAP during the CsA treatment period after BMT (days 0-21), as well as during the
post-CsA period.
In the immediate post-BMT period, conditioning and CsA treatment resulted in
elevated production of inflammatory mediators. It was demonstrated that mice treated
with CsA had increased levels of oxidative stress shown by increased levels of the ROS
probe DCFH-DA. Staining of spleen lymphocytes taken from control BMT and CsAtreated mice at day 21 post-CsA (Figure 3.1, A) and 2-3 weeks post-CsA therapy
(Figure 3.1, B) revealed increased levels of this ROS marker in CsA-treated mice
compared to transplant controls. Reactive nitrogen species were also elevated in the CsAtreated animals compared to their control. Real time RT-PCR analysis revealed elevated
mRNA levels of iNOS in colons of CsA-treated mice (Figure 3.2, A) and analysis of the
serum showed elevated circulating nitrate in CsA animals (Figure 3.2, B) compared to
control BMT. Along with increases in oxidative stress, our group has shown increased
mRNA levels of TNF-α in the colons of CsA-treated mice compared to control BMT at
several time points during and post-CsA therapy (Figure 4.3). It is known that irradiation
can trigger TNF-α expression in many cell types and reports show that TNF-α signaling
is associated with increased oxidative stress [94, 152]. Collectively, our results confirm
that CsA-treated mice produce increased levels of oxidative stress compared to control
transplanted mice.
Simmonds et al. previously published a direct correlation between increased
production of ROS and increased pathogenesis in colorectal biopsy specimens of patients
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with inflammatory bowel disease [153]. Similarly, Rachmilewitz et al. also reported
increased concentrations of RNS (i.e. NO) in ulcerative colitis and Crohn’s disease
patients [154]. Thus, evidence exists of increased oxidative stress intermediates in IBD
which could participate in the cellular damage and chronic inflammation observed in
intestinal inflammation. Such findings point to the potential of antioxidant therapy as a
possible curative option to ameliorate the deleterious effects caused by oxidative stress.
Several studies have concentrated on the use of antioxidant therapy as an option to treat
colitis and results reveal positive outcomes [155, 156]. The use of antioxidants to
promote graft acceptance in animal models has also been successful, supporting the role
of ROS/RNS in rejection [157]. In addition, antioxidant therapy in a murine model [158]
as well as in a clinical trial [62] of GVHD has also been shown to improve disease
outcome. These studies led us to the hypothesis that antioxidant therapy could ameliorate
the inflammatory response observed in the colons of SGVHD animals.
The potential and beneficial effect of SOD mimetics have been demonstrated in
many studies, highlighting the importance of antioxidant compounds as potential
therapeutic treatment for many pathologies (i.e. renal and myocardial ischemia and
reperfusion (I/R) injury, inflammatory conditions, pulmonary diseases) [126, 133-135,
151]. Therapy of CsA-treated mice with MnTBAP either during (Figure 3.4) or post-CsA
(Figure 3.7) treatment resulted in the reduction of clinical symptoms and total disease
induction. The use of antioxidant therapy in the murine model of SGVHD also reduced
mRNA levels of iNOS (Figures 3.5, A and 3.8) and TNF-α (Figure 3.5, B) along with
decreased nitrotyrosine staining (Figures 3.6, 3.9) in colonic tissue of CsA-treated mice
compared to mice receiving CsA alone. These results demonstrated that MnTBAP
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therapy of CsA-teated mice was capable of reducing RNS (i.e. iNOS and ONOO-),
avoiding the possible damage caused by their elevated levels and/or their downstream
products (i.e. radical-driven oxidative events). Peroxynitrite has been shown to change
cell membrane rigidity and permeability as well as to induce cell death in renal epithelial
cells [159]. A reduction in peroxynitrite could explain why MnTBAP treatment delayed
the clinical symptoms of SGVHD by reducing ONOO⎯ induced damage to epithelial
cells, resulting in reduction in diarrhea and weight loss. In addition to reducing
proinflammatory mediators, MnTBAP therapy during CsA treatment also reduced the
levels of CAM (data not shown) which contribute to the inflammatory response observed
in this inducible disease (discussed in Chapter Four of this dissertation), The link that
exists between CAM and lymphocyte homing to the site of inflammation has been
documented in many pathologies [109, 113, 116, 160]. Thus MnTBAP-induced
downregulation of CAM could affect lymphocyte homing to the inflamed gut observed in
SGVHD.
Since the role of CD4+ T cells has been well established in the pathogenesis
observed in murine SGVHD [78, 161] and MnTBAP is capable of reducing CAM which
contribute to T cell homing into the gut [109, 110, 116] (Chapter Four and discussed
below), it could be hypothesized that antioxidant treatment could reduce the migration of
CD4+ effector T cells into the colon of CsA-treated animals prior to development of
disease. However, our results showed that the cellular inflammatory response observed in
the colon of SGVHD was not reduced by MnTBAP treatment (Figure 3.10) and CD4+ T
cells still migrated into the colons of CsA-treated mice after antioxidant therapy (Figure
3.11). These interesting findings suggest that while MnTBAP decreased some
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inflammatory mediators (i.e. iNOS, TNF-α and CAM), as well as reduced clinical
symptoms and delayed disease induction, treatment of mice with this antioxidant was not
enough to prevent the histological changes observed in the SGVHD colon. Since the
effector cytokines and CAM were not significantly reduced by MnTBAP, these changes
may not have been enough to alter the migration of effector cells into the gut, but may
reduce the negative effects of oxidative stress on the development of clinical symptoms.
The pathophysiology caused by ONOO⎯ on gut inflammation (i.e. IBD) has been difficult
to predict since there are many oxidative mediators present during intestinal
inflammation and neutralization of a specific mediator has been difficult. However,
evidence does exist that both ROS and RNS are elevated in IBD, but their exact
contribution remains unclear due to the lack of specificity of these scavengers [99].
MnTBAP has been commercially sold as an SOD mimetic and there is some
recent evidence that it may not be a specific scavenger of superoxide [133, 137].
Experiments using this compound suggested that commercial MnTBAP is unable to
dismutate superoxide in vivo and has been reported to likely scavenge peroxynitrite and
carbonate radicals [133]. In our attempt to discover the mechanism of action by which
MnTBAP delayed the development of SGVHD, we analyzed mRNA levels of antioxidant
enzymes including: SOD, catalase, glutathione reductase (GPx) and NADPH reductase.
Real time RT-PCR results revealed that MnTBAP treatment had no effect on any of these
antioxidant enzymes (data not shown) in the murine model of SGVHD. These results
were surprising since other publications have shown that MnTBAP treatment induces
upregulation of antioxidant enzymes [162, 163]. However, there is also evidence that the
preconditioning requirements (irradiation and CsA) of SGVHD by themselves can
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downregulate antioxidant enzyme activity [66, 164, 165], thus it is possible that the
regimens induced oxidative stress via the downregulation of antioxidant defenses which
could not be overcome by MnTBAP treatment. Analysis of nitrotyrosine deposition
revealed decreased immunohistochemical staining of this marker, suggesting that
MnTBAP antioxidant action may be through inhibiting tyrosine nitration rather than
scavenging super oxide [133]. In addition, Cooke et al. showed that under oxidative
stress, ONOO⎯ formation is enhanced, resulting in a positive loop that increases iNOS
through the activation of NF-κB.

The possibility exists that MnTBAP treatment

scavenged ONOO⎯ resulting in the reduction of NF-κB-induced expression of iNOS that
we observed in the murine model of SGVHD [166]. This could explain why MnTBAP
treatment both during and post-CsA period was able to reduce iNOS mRNA levels in
colonic tissue of CsA-treated mice. Flanagan et al. demonstrated that SGVHD can be
reduced following treatment with the iNOS inhibitor AG during the post-CsA period
[100]. In their studies, AG therapy of CsA-treated mice resulted in decreased tissue
pathology along with reduced mRNA levels of proinflammatory cytokines (i.e. IL-12 and
IFN-γ). Surprisingly, in our studies, antioxidant therapy of CsA-treated mice with
MnTBAP did not have the same effect.
Differences between these therapies may rely in their mode of action.
Aminoguanidine specifically inhibits iNOS [104] by causing covalent modifications of
the iNOS protein and the heme residue at the active site resulting in inactivation of iNOS
[167]. Meanwhile, MnTBAP has been reported to scavenge a broader spectrum of
oxidative stress mediators. Thus, it is possible that while AG treatment was able to
effectively shut down iNOS enzymatic activity and the generation of RNI, MnTBAP
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therapy only decreased it partially through negative feedback loops [166] which resulted
in a reduction in the production of NO and downstream generation of ONOO⎯. Flanagan
et al. demonstrated a role for NO in the pathogenesis observed in SGVHD but the
mechanism of NO-induced inhibition remained unclear. It was unknown if AG action
was via the reduction of cytotoxic processes or via the reduction of inflammatory
cytokines. Tissues isolated from SGVHD animals treated with AG revealed decreased
mRNA levels for IL-12 and IFN-γ, suggesting NO participated in the production of these
cytokines [100]. This finding is consistent with the studies of Zhao et al. [168] showing
that NO can upregulate the production of IL-12 by alveolar macrophages. Meanwhile in
the current studies outlined in Chapter Three of this dissertation, MnTBAP therapy did
not decrease mRNA levels of these proinflammatory cytokines (Figure 3.6), which are
known to mediate disease induction [80]. It has been shown that NO enhances IL-12
production which in turn stimulates NK cells to produce IFN-γ [169], suggesting that NO
is a prerequisite for cytokine signaling and function. Our results support the idea that NO
acts upstream of the induction of these proinflammatory cytokines since iNOS mRNA
levels are significantly upregulated as early as day 14 post-BMT whereas significant
increases of IL-12 or IFN-γ are not detected until day 21 post-BMT [100]. This could
explain why AG treatment was able to decrease tissue pathology, while MnTBAP
treatment did not, by reducing NO-induction of proinflammatory cytokines. Thus, while
MnTBAP can alter NO production and other processes associated with RNS, it may not
be as effective as AG in altering SGVHD pathology.
The preconditioning regimen of SGVHD, which includes irradiation and CsA, are
both known to participate in the generation of oxidative stress. The data presented in
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Chapter Three of this dissertation confirms the hypothesis that SGVHD induction results
in increased oxidative stress in CsA-treated mice compared to BMT controls. Treatment
with a commercially available SOD mimetic, MnTBAP, during the 21 days of CsA
period as well as post-CsA treatment resulted in delayed disease induction and clinical
symptoms of SGVHD. However, based on the findings outlined in this dissertation, we
conclude that the reduction of proinflammatory mediators and oxidative stress was not
sufficient to completely ameliorate disease induction.

5.3

Role of T cell homing in SGVHD
Leukocyte homing from the blood to different compartments of the body

is governed by complex signal cascades and interactions involving selectins and
integrins, found on the inflamed tissue, and their respective ligands on the surface of
lymphocytes [2]. A role for CD4+ T cells in the development of SGVHD has clearly been
established [58, 78]. First, tissue analysis revealed an increased percentage of CD4+ T
cells in the SGVHD colons and further characterization confirmed these findings [78]. In
vivo depletion studies using a mAb containing a cocktail against T cells during the postCsA period failed to inhibit disease [80] and subsequent analysis revealed that antibody
treatment was able to remove peripheral CD4+ T cells but not colonic T cells [78] thus
not altering SGVHD induction. Expanding on these studies, the use of specific mAb
against CD4+ T cells, following myeloablative conditioning and during the 21 days of
CsA therapy period, significantly reduced the induction of clinical symptoms as well as
pathology associated with murine SGVHD [78]. Along these findings, there is also
evidence that CD4+ T cells isolated from SGVHD mice are capable of inducing disease
when adoptively transferred into secondary recipients [58]. Taken together, these findings
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demonstrate that the presence of CD4+ T cells in the colons of CsA-treated mice during
the induction period is critical for disease development. In Chapter Four of this
dissertation, experiments were performed to follow up on the observation that CD4+ T
cells accumulate in the colon during CsA therapy [80] and to study potential mechanisms
involved in trafficking of these cells into the colon of CsA-treated mice. Real time RTPCR mRNA analysis revealed increased levels of the proinflammatory cytokine TNF-α
(Figure 4.3), as well as CAM (Figures 4.4 and 4.6) in colonic tissue of CsA-treated
mice compared to control BMT as early as day 14 post-BMT. In addition, chemokines
associated with the migration of T cells into mucosal tissues were also significantly
elevated in the CsA-treated mice by day 21 post-BMT (Figure 4.6). Concurrent with
these results, lymphocytes isolated from the colons of CsA-treated mice showed a
significant increase in the percentage of CD4+ T cells compared to control animals
(Figures 4.1 and 4.2).
The conditioning agents of SGVHD (CsA and irradiation) have been shown to
damage the vascular endothelium [92, 170] resulting in the upregulation of
proinflammatory cytokines such as TNF-α. It was proposed that this inflammatory
cascade resulted in the upregulation of CAM, which in turn enhanced the recruitment of
leukocytes to the site of inflammation. Numerous studies have shown the important
function that CAM have in different pathologies, as well as their role in lymphocyte
homing to the inflamed organ [108-110, 116, 117, 142, 160]. Since our studies
concentrated on the colon, we focused on the expression of MAdCAM-1 because it has
been previously demonstrated to be essential in the induction of intestinal GVHD [117].
The α4β7 integrin serves as the ligand for MAdCAM-1 and their interaction has been
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strongly implicated in directing the recruitment of lymphocytes to the inflamed intestine
[117, 171]. Eyrich et al. have shown that irradiation enhances the expression of VCAM
and ICAM, but not MAdCAM by three days after radiation conditioning and syngeneic
BMT [117]. The expression of these molecules subsided by nine days after BMT.
Additional signals involved in the induction of allogeneic GVHD were required for the
upregulation of MAdCAM in these studies. These additional signals were likely
generated as a result of the allogeneic T cell response associated with the development of
allogeneic GVHD. Based on the sequential expression of CAM following allogeneic
BMT and GVHD induction [117], and the enhanced migration of CD4+ T cells into the
colon during CsA treatment in the SGVHD model, studies were initiated to examine the
expression of CAM after BMT, during the CsA treatment period (d0-d21). Analysis of
colonic tissue revealed significantly increased mRNA levels of CAM as early as day 14
post-BMT in CsA-treated mice compared to control BMT (Figures 4.4 and 4.5).
Concurrent with these findings, significantly elevated levels of CD4+ T cells were also
observed in the colon of CsA-treated mice at this early time point (Figures 4.1 and 4.2).
It should be noted that in contrast to the CsA therapy of BMT mice, preliminary studies
have shown that treatment of normal, non-irradiated animals with CsA did not induce the
influx of CD4+ cells into the colon (data not shown), further demonstrating the dual
requirement for pretransplant conditioning and CsA treatment in the development of
SGVHD [57, 85, 97]. In addition, TNF-α mRNA levels were also significantly elevated
by day 14 post-BMT in the colon mice treated with CsA compared to transplant control
(Figure 4.3). Since the level of this proinflammatory molecule was significantly elevated
during the CsA period, preliminary experiments were performed to analyze the role that
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TNF-α may have in the induction phase of SGVHD. However, attempts to decrease
TNF-α, by in vivo neutralization, was associated with a high mortality rate in the treated
animals. Similar results have been previously reported in which TNF-α neutralization in
the early post-BMT period resulted in increased mortality in an allogeneic BMT model
system [172]. These results suggest that TNF-α has a protective effect during the early
stages after BMT and is essential for recipient survival.
Histological evaluation of colonic tissue during active disease, as well as analysis
of isolated cells, has led to the recognition that the severe colonic tissue damage observed
in SGVHD mice is caused by an infiltration of inflammatory CD4+ T cells into the colon
of CsA-treated mice [55, 78, 80, 83, 100, 139]. The mechanism by which effector T cells
are recruited into the gut during the inflammatory response of SGVHD remains unclear
but a potential contributor likely involves chemokine gradients. Chemokine interactions
with their corresponding receptors have been implicated in many inflammatory processes
via their ability to attract effector cells to the sites of inflammation [112, 113, 160].
Several studies have been able to characterize chemokines highly expressed during gut
inflammation which include CCR5, CCL3, CCL5 and CCL20 [112, 113]. We therefore
analyzed the mRNA expression of these chemokines in colonic tissue and similar to the
elevated levels of CD4+ T cells and CAM, these chemokines associated with gut
inflammation were also significantly increased in the colon of CsA-treated mice by day
21 post-BMT compared to control (Figure 4.6). The mRNA levels of these chemokines
were also evaluated at day 14 post-BMT but at this time point only CCR5, which is
expressed on the surface of activated lymphocytes, was significantly elevated (data not
shown). However, its ligands (CCL3 and CCL5) were only slightly, but consistently
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elevated, when compared to control BMT. No difference was observed in mRNA levels
of CCL20 by day 14 post-BMT. While activated lymphocytes expressing CCR5 were
present by day 14 post BMT, its counterligands, released by the tissue, were not yet upregulated at this early time point, suggesting that other ligand-receptor pairs may be
involved in the early homing of these T cells into the intestines of CsA mice. Changes in
the expression levels of homeostatic chemokines, including CCL19, CCL21, CCL25,
CCL28, as well as CXCL13 have been shown to be increased in IBD [113]. Thus, we
cannot discard the possibility that other mediators are involved in the recruitment of these
CD4+ T cells to the inflamed tissue since high levels of redundancy are involved in
chemokine receptor function and inflammatory responses.
To determine if the increases in CAM and chemokines were functional during the
SGVHD induction period, a long-term CD4+ T cell line, originally isolated from diseased
animals, was used for lymphocyte trafficking studies. Previous results [58] and
unpublished data, have demonstrated that an increased frequency of CD4+ T cells in
lymphoid cells isolated from SGVHD animals are reactive against microbial antigens
present in the cecum of normal mice. Phenotypic analysis of these cells showed that they
express β7 integrin, which is a type of integrin expressed on the cell surface of activated
lymphocytes and allows for their interaction with cell adhesion molecules (MAdCAM-1,
VCAM-1) present in the inflamed gut. Our results showed increased mRNA levels of
these CAM in colonic tissue of CsA-treated mice compared to control BMT as early as
day 14 post-BMT (Figures 4.4 and 4.5). Concurrent with these findings, preliminary
studies on IEL, isolated from the colon of control and CsA-treated mice at several time
points during the induction protocol, revealed a 2-fold increased in CD4+β7+ lymphocytes
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in the colons of CsA animals by day 14 pos-BMT (data not shown). These results
allowed us to hypothesize that CD4+ T cells, isolated from diseased animals and bearing
the β7 integrin, would preferentially migrate into the colon of CsA-treated mice which
express elevated levels of CAM. Homing studies performed by i.v. inoculation of the
labeled CD4+ SGVHD T cell line at day 21 post-BMT, revealed their increased migration
into the colon of CsA-treated mice compared to control BMT, suggesting a functional
role for the increased CAM and inflammatory mediators present in the intestines of CsAtreated mice. In this study, the migration and distribution of these CD4+ T cells was also
analyzed in other tissues including the liver, spleen and lung. In addition to the intestine,
increased numbers of these labeled CD4+ T cells were also observed in liver tissue of
CsA-treated mice compared to control BMT animals, although not to the extent observed
in the colon (data not shown).
The results presented in the Chapter Four of this dissertation demonstrates that
during the 21 days of immunosuppressive therapy there is an ordered increase in the
expression of inflammatory mediators and CAM that is associated with the increased
migration of CD4+ T effector cells into the colon, leading to the development of the
colonic inflammation associated with murine SGVHD.
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5.4

Proposed mechanism underlying oxidative stress and T cell role in

the pathogenesis observed in murine SGVHD
To summarize our findings, we propose the following mechanism for the
involvement of oxidative stress and T cell homing in murine SGVHD. Total body
irradiation is a preconditioning regimen required for the induction of SGVHD. It is
known that it upregulates production of oxidative stress as well as proinflammatory
cytokines. As a consequence, immune cells along with ROS/RNS mediate tissue damage
and initiate a cascade of inflammatory responses. Damage to the gastrointestinal tract
allows for increased translocation of LPS and other microbial molecules into the systemic
circulation. These bacterial products can lead to the stimulation of macrophages to
produce proinflammatory mediators like TNF-α, IL-12 and NO. Tumor necrosis factor-α
can in turn activate NF-κB induction of gene transcription of proinflammatory molecules
resulting in increased cytokines, adhesion molecules and oxidative stress mediators
involved in immune and inflammatory responses. In turn, IL-12, also known as a T cell
stimulating factor, can stimulate the growth/function of the CD4+ T cells known to
mediate SGVHD, resulting in the production of IFN-γ which can feed back and further
enhance macrophage activation. Macrophages can produce NO via iNOS leading to
inflammation by upregulation of oxidative stress mediators. Nitric oxide by itself is a
weak free radical but its combination with other ROS, like superoxide (O2-), can result in
the formation of peroxynitrite (·O2− + ·NO → ONOO−), a very toxic and reactive product
capable of mediating several cytotoxic processes. CsA, another preconditioning agent of
SGVHD, is also involved in upregulation of oxidative stress and its proposed mechanism
is via the down regulation of antioxidant enzymes leading to the accumulation of
108

ROS/RNS. All these proinflammatory mediators can then act in concert to induce the
lesions and pathology observed in the colon of SGVHD mice.
In addition, the elevated inflammatory signals (TNF-α, oxidative stress
mediators/products) can also upregulate CAM on the surface of HEV present in the
epithelium, allowing for the homing and extravasation of lymphocytes into the gut. APC
present at the site of inflammation migrate into the MLN were they present microbial
antigens and activate CD4+ T cells. Once activated, these CD4+ T cells express in their
surface β7 integrin which allows for their interaction with CAM present in the inflamed
colonic tissue. Chemokines released by the tissue serve to attract these CD4+ T cells to
the site of inflammation. The colonic CD4+ T cells can further enhance other effector
cells, expanding the inflammatory response leading to tissue damage. Activation of CD4+
T cells in the MLN/colon leads to an IBD-like disease that moves from the colon to the
liver by aberrant expression of CAM (MAdCAM-1) and chemokines (CCL25) that are
typically restricted to the epithelium of the gut mucosa. These CD4+ T cells, as well as
other inflammatory cells (macrophages, Kuppfer cells, dendritic cells (DC)), work
together to mediate intra- and extra-hepatic liver inflammation that develops subsequent
to the colonic inflammation (see Figure 5.1).
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5.5

Future directions
The studies performed in this dissertation offer new findings that contribute to the

understanding of the IBD-like colitis observed in murine SGVHD. Besides the
contributing knowledge that these results provide they also give rise to further questions
which require additional studies for their analysis.
In Chapter Three of this dissertation the role of oxidative stress in the
development of SGVHD is discussed. Even though treatment with the antioxidant
MnTBAP delayed disease induction it was not sufficient to inhibit disease or the
contributing effector cells and cytokines associated with the pathology observed in
SGVHD animals. The usage of this antioxidant at a higher dose (20 mg/kg, twice a day)
but still under the safe concentration to be used following a toxicological report, resulted
in increased mortality of mice (data not shown). Suggesting that combined treatment of
CsA along MnTBAP had a toxic effect on mice, which was confirmed by increased
pathology in colon and liver samples. In addition, MnTBAP action on scavenging
ROS/RNS mediators has been somehow controversial and could result in misleading
conclusions. It is evident that oxidative stress is increased in CsA-treated mice compared
to control BMT but its exact contribution to the development of murine SGVHD during
the 21 days of immunosuppression therapy remains unclear, thus requiring further studies
to better analyze this matter. This approach can be studied by the use of a more specific
antioxidant, like M40403, which is an SOD mimetic that specifically scavenges super
oxide anions at a high rate, inhibiting its interaction with other biological oxidizing
agents. This could provide a better understanding and specificity of the role of super
oxide in SGVHD.
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The role of T cell homing in SGVHD was discussed in the fourth chapter of this
dissertation leading to the findings that there are mechanisms occurring during the period
of CsA treatment that allow for increased migration of CD4+ T cells into the colon of
CsA-treated mice compared to control BMT. Cell adhesion molecules seem to be
implicated in the homing of these T cells into the gut, specifically MAdCAM-1 via its
interaction with α4β7+ present in the surface of activated T cells. Although significant
increases in both CAMs and β7+ were present in colonic tissue of CsA-treated mice
immunoblockade studies were not undertaken to confirm the role of these mediators in
murine SGVHD. Further in vivo studies either blocking MAdCAM-1 or α4β7+ are
required to study their effect on T cell migration and SGVHD outcome.
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Figure 5.1 Role of oxidative stress and T cell homing in murine SGVHD

Figure 5.1 Role of oxidative stress and T cell homing in murine SGVHD. Irradiation
and CsA treatment upregulate the production of oxidative stress as well as
proinflammatory cytokines. Damage to the GI tract allows for increased translocation of
bacteria products which stimulate MΦ to produce proinflammatory mediators.
Chemokines released by the tissue serve to attract bacterial-specific CD4+ T cells to the
site of inflammation, expanding the inflammatory response and leading to further tissue
damage. Activated CD4+ T cells move from the colon into the liver by aberrant
expression of MAdCAM-1 and CCL25 that act in concert with other inflammatory cells
to mediate the liver inflammation that develops subsequent to the colonic inflammation.
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Appendix. Reagent Preparation
Phosphate Buffer Saline (PBS) Solution:
For a 10X solution:
1. Add 92 g of NaH2PO4 (dibasic) to 4 liters of distilled water
2. Heat solution to 60⁰C in a water bath, stirring periodically to dissolve
3. While solution is still stirring, add 16 g of KH2PO4
4. Adjust pH to 7.2
5. Add 654.4 g NaCl to the stirring solution
6. Bring total volume to 8 liters with distilled water
7. Store at room temperature
For a 1X solution:
1. Combine 100 ml of 10X PBS with 900 ml distilled water
Paraformaldehyde solution:
For a 1% paraforlmaldehyde solution:
1. Combine 1 g paraformaldehyde with 25 ml of distilled water and incubate in a
56⁰C water bath, stirring occasionally until dissolved
2. Add 5 ml of 10X PBS and 20 ml distilled water to the solution and mix
3. Add 5 ml of 10X PBS and 45 ml distilled water to the solution and mix
4. Adjust pH to 7.4
5. Filter solution and place in a 100 ml bottle
6. Store at 4⁰C refrigerator
For a 3% paraforlmaldehyde solution:
1. Prepare 1 liter of 0.1M PBS by mixing 3.58 g NaH2PO4●2H2O (monobasic) +
10.94 g NaH2PO4 (dibasic) and complete to 1 liter with distilled water
2. Add 30 g of paraformaldehyde to 900 ml of PBS
3. Heat solution to 60⁰C in a water bath, stirring periodically, until solution is clear
4. Allow solution to cool to room temperature
5. Adjust pH to 7.2-7.4
6. Bring total volume to 1 liter with PBS
7. Store at 4⁰C
Tris-buffer stock:
1.
2.
1.
3.
4.

Dissolve 20.59 g of Triza Base into 800 ml distilled water
Adjust pH to 7.2
Bring total volume to 1 liter with distilled water
Autoclave 20 min, slow exhaust to sterilize
Store at room temperature
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Tris-buffered ammonium chloride:
2.
3.
4.
5.
6.
7.

Dissolve 8.3 g of NH4Cl in 800 ml of distilled water by stirring
Add 100 ml of Tris-buffer stock, pH 7.2
Adjust pH to 7.2
Bring total volume to 1 liter with distilled water
Dispense into 100 ml bottles and autoclave 20 min, slow exhaust to sterilize
Store at room temperature

Heat Activate Fetal Bovine Serum (FBS):
1. Take out FBS from -20⁰C and allow flask to thaw in a 37⁰C water bath, stirring
occasionally
2. Once thawed, transfer FBS to 60⁰C water bath for 45 minutes
3. Allow to cool down at room temperature
4. Store at 4⁰C
Complete Media (RPMI 1640):
1. Add Fetal Bovine Serum (FBS):
• For 10% media: 50 ml of FBS for each 500 ml bottle of RPMI
• For 5% media: 25 ml of FBS for each 500 ml bottle of RPMI
2. Add 5 ml of penicillin/streptomycin/glutamine (100X)
3. Add 5 mM 2-mercaptoethanol (2-ME)
4. Store at 37⁰C
Cytotoxic Media (RPMI 1640):
1. Add 5 ml of penicillin/streptomycin/glutamine (100X) and 20 ml of bovine serum
albumin (BSA) to one bottle of 500 ml RMPI
2. Store at 37⁰C
Hepes Bicarbonate Buffer:
1.
2.
3.
4.

Combine 23.8 g of Hepes with 21 g of NaCl
Bring total volume to 1 liter with distilled water
Adjust pH to 7.2
Transfer into a sterile flask and store at room temperature

0.5 M EDTA Solution:
1.
2.
3.
4.
5.

Dissolve 16.81 g of EDTA in 90 ml of distilled water
Adjust pH to 7.2
Bring total volume to 100 ml with distilled water
Autoclave 20 min, slow exhaust to sterilize
Store at room temperature
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CMF Solution:
1. Combine 100 ml 10X Hanks (Ca2+, Mg 2+free), 100 ml 10x Hepes bicarbonate
buffer and 20 ml FBS
2. Bring total volume to 1000 ml with distilled water
3. Filter sterilize and store at 4⁰C
CMF/FBS/DTE/EDTA Solution;
1. Combine 184 ml CMF, 16 ml FBS, 0.2 ml DTT (1M) and 0.4 ml EDTA (0.5M)
2. Prepare fresh and place in 37⁰C water bath until use
10% Complete /Collagenase Type VIII/DNaseI Solution:
1. Combine 80 ml 10% complete RMPI, 69.3 mg Collagenase (277U/mg) and
0.080 mg DNaseI (2000U/mg)
2. Prepare fresh and place in 37⁰C water bath until use
Percoll Soutions:
1. Prepare a 1X stock solution by diluting 90 ml Percoll with 10 ml of 10X PBS
2. For a 44% Percoll solution: Mix 44 ml of 1X stock and 56 ml 5% complete
medium
3. For a 67% Percoll solution: Mix 67 ml of 1X stock and 33 ml 5% complete
medium
4. Adjust pH to 7.2
5. Prepare fresh and place on ice until use
FACS Staining Buffer:
1. Combine 5 ml FBS, 50 mg NaN3 into a flask containing 500 ml 1X PBS and mix
to dissolve
2. Store in 4⁰C
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